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ABSTRACT
The major histopathologic hallmark of Alzheimer’s disease (AD) is the presence
of (3-amyloid plaques that are often associated with reactive microglia in the brain. It has
been suggested modulating the microglial phenotype to attenuate an inflammatory
response may prove to be useful in determining therapies for prevention or delay of the
disease. My dissertation supports he hypothesis that Ap stimulates microglial activation
through a specific tyrosine kinase-dependent response involving the Src kinase family.
Using primary mouse microglia we observed that both fibrillar and oligomeric Ap
stimulated increased microglial protein phosphotyrosine levels including active levels of
the kinase Src and a subsequent increase in secretion of the cytokine, tumor necrosis
factor alpha (TNFa). This response was attenuated by using a Abl/Src family kinase
inhibitor, dasatinib. Intracerebroventricular infusions of AP oligomer into C57BL/6 adult
mice elevated hippocampal phosphotyrosine levels and microgliosis that were attenuate
by dasatinib treatment. To evaluate the efficiency of dasatinib in a relevant transgenic
model of AD, drug was subcutaneously infused into 13-month old APP/PS1 transgenic
mice. Behavioral testing using T-maze showed better performance from dasatinib infused
mice as compared to vehicle treated and control animals. Biochemical analyses
demonstrated that dasatinib infused animals had lower total protein phosphotyrosine and
pSrc levels in the hippocampus. Dasatinib is an FDA approved drug for treating chronic
myeloid leukemia and can cross the blood brain barrier. Our demonstration of the
microglial inhibitory action of this drug defines a novel use. Based upon the observation
x

that AD brains showed increase in active, phosphorylated Lyn levels in reactive
microglia, this kinase may also represent a possible microglial inhibitory target as well.
Following a high throughput screening kinase assay, four drugs were identified. One
compound LDDN-0003499 inhibited total protein phosphotyrosine as well as active pLyn
levels in BV2 microglial cell line. LPS stimulated microglia treated with LDDN-0003499
demonstrated attenuation of TNF-a levels secretion. Collectively, our data supports the
idea that non-receptor tyrosine kinase inhibition could be an important therapeutic goal
for prevention and/or delay of AD.
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CHAPTER 1
INTRODUCTION
Alzheimer’s disease
Alzheimer’s disease is the most common form of dementia. It affects mainly the
elderly with a prevalence o f 5% after 65 years of age and increases to about 30% at 85
years of age. AD is mainly characterized by cognitive impairment that affects thinking
and behavior, severe enough to interfere with daily life (McKhann et al., 1984). It is a
progressive form of disease that gets worse over time. At present, 5.3 million Americans
are suffering from AD, with over 26 million people affected worldwide. According to the
World Alzheimer’s Report, the total estimated costs of dementia in US was $604 billion
in 2010 with about 70% of that occurring in Western Europe and North America. Apart
from the huge economic burden, this disease presents a tremendous amount of emotional
and physical stress to not only the patients but also the care-givers of people suffering
with Alzheimer’s disease.
The disease was first described in 1906 by German psychiatrist and
neuropathologist, Alois Alzheimer, when he observed in a patient, strange behavioral
symptoms, including loss in short-term memory. Brain autopsy showed various
abnormalities including a thinner cerebral cortex than normal and the presence of senile
plaques and neurofibrilary tangles. Although the cause and progression of
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Alzheimer’s disease are not well understood, it has been very well established that the
histopathology of AD consists of these two distinct characteristics, the presence of
tangles and plaques (Dickson, 1997). These neurofibrilary tangles are mainly found in
neurons in the brain regions affected by AD and are composed of protein tau, that is
aggregated as paired helical filaments (PHF) (Hernandez and Avila, 2007). Tau is
normally associated with microtubules that represent a component of structural support
for intracellular transport (Weingarten et al., 1975; Drubin and Kirschner, 1986). Under
normal conditions, tau has a role in stimulation and stabilization of microtubules.
However in AD, tau is hyperpho sphorylated which inhibits its ability to provide
microtubule assembly and it aggregates as insoluble deposits within the cells (GrundkeIqbal et al., 1986). The other major histopathological marker of AD is the presence of
senile plaques, which are insoluble fibrous protein aggregates of amyloid-|3 peptide
(Selkoe, 1994). This peptide is the cleavage product of a transmembrane integral protein,
amyloid precursor protein. Plaques and tangles are predominantly found in frontal and
temporal cortex regions of the brain, including the memory and visuospatial center, the
hippocampus (Ray et al., 1998). Whether plaques and tangles play a causative or
consequential role in the progression of Alzheimer’s disease is still not well understood.
Clinically, Alzheimer’s disease progression is marked by different stages o f very
mild/mild cognitive impairments (MCI), mild, moderate and severe dementia (Morris,
1993; Petersen et al., 1999). These stages correlate with increasing abundance of
amyloid-plaques, neurofibrilary tangles and loss of neuronal and synaptic markers.
Figure 1 adapted from (Perrin et al., 2009) illustrates the progression of changes of the
various characteristic biomarkers of AD over time with relation to the appearance of
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clinical stages in an AD brain. Amyloid-fi plaques occur in the pre-clinical stages o f AD
for 10-15 years, eventually leading to damages in neuronal integrity (Morris, 1993).
Neuronal loss is associated with onset of dementia as well as an increase in neurofibrilary
tangles. The major biomarkers of AD include an increase in CSF tau and phosphorylated
tau, a decrease in CSF Af)42, microgliosis, inflammation, increase in markers oxidative
stress, brain atrophy and genetic predisposition (Sunderland et al., 2003; Galimberti et ah,
2008; Kauwe et ah, 2009; Reddy et ah, 2009). For diagnostic purposes, advanced medical
imaging techniques like computer tomography (CT) or magnetic resonance imaging
(MRI) and positron emission tomography (PET) can be used to determine the cerebral
topography, but it is difficult to predict the earliest stages of AD. These diagnostic tools
may predict the subtype of dementia or conversion from MCI to AD. However, apart
from genetic predisposition, it is difficult to monitor the occurrence of AD progression in
the early stages of the disease (Craig-Schapiro et ah, 2009; Perrin et ah, 2009)
AD can be classified into two forms, Familial Alzheimer’s disease (FAD) and the
Sporadic Alzheimer’s disease (SAD). The familial form of the disease is uncommon and
accounts for 5% of the cases and is usually defined at an earlier age. Also known as
Early-onset AD, autosomal dominant mutations in APP, Presenilin 1 (PSEN1) and
Presenilin 2 (PSEN 2) genes has been linked with the familial form of the disease. The
sporadic form of AD accounts for 95% of the cases and has been linked to a number of
environmental factors along with synergistic actions from genetic factors. These include
cardiovascular diseases. Type 2 diabetes, mid-life obesity, increased age as well as
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polymorphisms in apolipoprotein E (ApoE) as risk factors (Stritlmatter and Roses, 1996;
Lendon etal., 1997; Patterson et al., 2008).

Figure 1. Proposed changes in biomarkcrs in relation to the time course of
pathological and clinical stages (Adapted with permission from (Perrin et al., 2009))
APP and Amyloid-p peptide
A tremendous amount of research has been performed to try to identify the role of
amyloid-p peptide in the pathogenesis of Alzheimer’s disease. The peptide is derived
from amyloid precursor protein (APP) which is ubiquitously expressed in neuronal and
non-neuronal cells (Selkoe, 1994). Non-amyloidogenic cleavage o f APP by a-secretase at
a site within the Ap domain, leads to the production of the soluble APP fragment, sAPPa,
and prevents the formation of AP peptide (Lammich et al., 1999). But the amyloidogenic
pathway of APP cleavage by p-seeretase followed by gamma-secretase action generates
the amyloid-P (AP) peptide (Fig. 2) (Gandy, 2005). Ap is a 4KDa peptide with
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microheterogeneiety in amino acid sequence with two physiologically relevant forms
A(3(_4o and A[51-42. AP 1-40 is the most abundant form o f the Afl present while A[51.42 form is
more prone to aggregation (Jarrett et al., 1993b; Yin et ah, 2007). Ap42 readily
multimerizes to form oligomers, then fibrils, and fully detergent resistant plaque
aggregates (Gandy, 2005). A[3.42, the more fibrillogenic form, is thus associated with
disease states, Mutations in APP associated with early-onset Alzheimer's have been noted
to increase the relative production of A[342 perhaps leading to accommodation of plaque
deposition and the early age of disease (Yin et ah, 2007).
One of the leading theories behind understanding of the causes o f AD pathology
is the amyloid cascade hypothesis (Hardy, 2006). This theory was proposed in 1992 by
Hardy and Higgins and has remained controversial over the years (Hardy and Higgins,
1992; Hardy, 1999, 2002). According to the hypothesis, A(3 plaque deposition is the main
cause of AD pathogenesis. APP proteolysis leading to accumulation and deposition of A (3
plaques is the initiating event that then leads to Af) dependent synaptic loss, neuritic
injury, altered signaling events and subsequent formation of neurofibrilary tangles and
cell death. Vascular damage and dementia follow as a direct effect of the deposition
(Hardy and Selkoe, 2002; Hardy, 2006). Because A|3 peptide forms the fibrillar core of
the senile plaques in both sporadic and autosomal dominant disease it has been
hypothesized that fibrillar A [3 deposition is mechanistically critical for disease (Jarrett et
ah, 1993a; Pike et ah, 1993). However, in recent years, evidence suggests a direct
correlation between cognitive impairment and synaptic loss with the levels of soluble
rather than fibrillar assemblies of A|3 extracted front AD brain (Lite et ah, 1999; McLean
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Aniyloidogenic
pathway

Protein (APP)

Figure 2: Schematic of Aniyloidogenic APP processing
et al., 1999). Oligomeric Af3 has been shown to be neurotoxic and synaptotoxic in vitro
studies as well (McLean et al., 1999; Sondag et al., 2009). A(3 oligomers have also been
linked to gliotic pro-inflammatory changes in vitro (Roller et al., 1996; Cleary et al.,
2005; Klyubin et al., 2005; Leslie et al., 2006; Klyubin et al.. 2008). The exact
contribution of the particular form of A|3 to disease, whether oligomeric or fibrillar, is yet
to be fully defined. However, the issue remains that in order to identify a prevention or
treatment therapy for AD, the role of Ap and the mechanism behind its gliotic and
neuronal actions need to be fully understood.
Microglia and AD
Microglia are the resident macrophages o f the brain and the spinal cord. They
form the first line of immune defense in the central nervous system. These cells constitute
6

about 5-20% of ail glial cells (Lawson et ai., 1992). In early stages of brain development,
microglia generally represent an “amoeboid” phenotype. They show a macrophage-like
morphology with a larger cell body and shorter processes (Ling, 1979). As the brain
develops, these microglia obtain a “ramified” morphology. These are the resting
microglia in a normal brain, with relatively longer processes and smaller cell bodies. In
cases of brain injury, or other neurodegenerative diseases, ramified microglia may
transform into activated states, also called “reactive microglia” (Nakajima and Kohsaka,
2001). These are morphologically distinct with longer, finger-like projections. The
reactive microglia become proliferative at the affected site. Activated microglia have
been implicated to play cytotoxic and inflammatory roles in the CNS (Poli, 1998; Weldon
et a!., 1998; Nakajima and Kohsaka, 2001; Rogers et al., 2002; Schlachetzki and Hull,
2009).
Microglia belong to the mononuclear phagocytic system, expressing characteristic
markers of phagocytes and immune cells, such as complement components and their
receptors, MHC glycoproteins and scavenger receptors (McGeer and McGeer, 1999;
Streit et al., 2004). Activated microglia are known to secrete cytokines as well as toxic
free radicals (Poli, 1998; Weldon et al., 1998; Akiyama et al., 2000; Jara et al., 2007). In
neurodegenerative diseases, microglia are known to show increased secretion of proinflammatory cytokines, chemokines and free radicals and reduced clearance of
pathological protein aggregates (like A[3) and cell debris, thus contributing to disease
pathogenesis (Dickson et al., 1993; Yates et al.. 2000; Tuppo and Arias, 2005; Block et
al., 2007).
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1he presence ot increased number of reactive microglia has been very well
characterized in Alzheimer’s disease (Fig. 3). Besides the accumulation of plaques and
tangles it has been shown in both human disease and transgenic mouse models, that
reactive microglia numbers are increased compared to non-demented controls and wildtype mice, respectively (McGeer et al., 1987; Akiyama and McGeer, 1990; Cras et al.,
1990; Styren et al., 1990; Frautschy et al., 1998; Stalder et al., 1999; Wegiel et al., 2001;
Sasaki et al., 2002; Wegiel et al., 2003). The morphologically distinct, activated
microglia are commonly associated with A(3 fibril containing plaques (Itagaki et al.,
1989; Mattiaee et al., 1990; Perlmutter et al., 1990; Mackenzie et al., 1995; Sasak. et al.,
1997; Akiyama et al., 1999; Benzing et al., 1999; Morgan et al., 2005; Meyer-Luehmann
et al., 2008). Numerous in vitro studies have demonstrated that AP Fibrils can directly
stimulate microglia to acquire a pro-inflammatory phenotype (Banati et al., 1993: Del Bo
et al., 1995; Giulian et al„ 1995; Klegeris et al.. 1997; Combs et al., 2000; Combs et al.,
2001a; Combs et al., 2001b). However oligomeric AP conformations have also been
reported to stimulate gliosis (Martin et al.. 1994; Sasaki et al., 1997; Sondag et al., 2009).
Indeed, up to 70% of diffuse plaques in non-demented aged individuals contain microglia
(Sasaki et al., 1997) suggesting that microglial interaction with nonfibrillar peptide is
common. Work from primates even indicates that gliosis precedes fibrillar plaque
deposition (Martin et al., 1994). Therefore, the fibrillar, insoluble form of the peptide
may not be the only substrates mediating neuronal death/dysfunction. More importantly,
the oligomeric peptide may represent a target for early disease therapy.
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HLA-DR (LN3)

AD
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Figure 3. Presence of reactive microglia in AD brain
Anti-inflammatory approach to AD
A plethora of data over the past 2 decades have led to the conclusion that
neuroinflammation forms an integral component of the pathogenesis of AD (Akiyama el
al., 2000; Strcit et al., 2004; Tuppo and Arias. 2005; Rojo et al., 2008; Agostinho et al.,
2010; McNaull et al., 2010; Schwab et al., 2010). Up regulation of various proinflammatory cytokines has been widely reported in AD patients (McGeer and McGeer,
1999: Streit et al., 2001; Szczepanik et al., 2001; Moore and O'Banion. 2002; Wilson et
al., 2002; Streit et al., 2004; Tuppo and Arias, 2005; Galimberti et al., 2008; Combs,
2009; McNaull et al., 2010). Microglia cultured from AD brains demonstrate marked
chemotaxis to AfS deposits (Rogers and L.ue, 2001) Microglia adhesion to A|) fibril
coated surfaces substantially increases reactive oxygen species production (El Khoury et
al., 1996). An increase in secretion o f pro-inflammatory cytokines 1L-Ip, IE-6 and TNFa, chemokines IE-8, macrophage and M EP-ln have been observed in microglia
interacting with Afi deposits (Rogers and l.ue. 2001). Pro-inflammatory changes have
9

been widely reported in transgenic mouse models of AD as well. Brains o f Tg 2576,
TgAPPsw, PSl/APPsw and triple transgenic mice (3XTg-AD), have all been reported to
have elevated levels of pro-inflammatory cytokines including IFN-y, IL-12, TNF-a, IL6,lL-ip, TGF-(3, IL-10, MCP-1 and GM-CSF (Benzing et al., 1699; Apelt and Schliebs,
2001; Abbas et al., 2002; Janelsins et al., 2005; Patel et al., 2005).
Modulation of inflammatory activity in these mouse models produces changes in
their AD-like pathology. For example, use of dominant negative-TNF inhibitors in triple
transgenics prevents intraneuronal A(3 accumulation (McAlpine et al., 2009). IFN-y
knockdown reduces A(3 plaque load and gliosis in Tg2576 mice (Yamamoto et a l, 2007).
Up-regulating pro-inflammatory pathways has also been reported to give rise to AD
pathology. For example, overexpression o f CCL2 (MCP-1) increases microglial
activation and A|3 deposition in APP/PS1 mice (Yamamoto et al., 2005).
Based upon the idea that manipulating microglial activity in various mouse
models can affect disease histopathology, it is reasonable to expect that similar alteration
of microglial phenotype will affect human disease. A number o f epidemiological studies
have demonstrated that long-term use of non-steroidal anti-inflammatory drugs
(NSAIDs) could be helpful in reducing the risk o f AD. The Rotterdam study in 2001
showed that long-term use o f ibuprofen reduced relative risk o f developing AD to 0.2
(95% Cl 0.05-0.83)(in't Veld et al., 2001). Use of ibuprofen. naproxen and indomethaein,
all NSAIDs demonstrated lower incidences of AD in the Baltimore study o f Aging
(Stewart et al., 1997). Use of NSA1D was also associated with a decrease in microgliosis
without affecting the A|) fibrillar plaque load (Mackenzie and Munoz, 1998). The most
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probable mechanism o f action ofNSAIDs is inhibition of COX-2 activity and
prostaglandin production, both linked to pro-inflammatory effects (McNaull et a!.. 2010).
In late onset AD. COX-2 activity has been found to be elevated in humans and it as also
been linked to APP processing and cognitive decline in animal models (Pasinetti and
Aisen, 1998; Tuppo and Arias, 2005; Rojo et al., 2008; McNaull et al., 2010). Besides
cox inhibition, NSAIDs have been proposed to work through inhibition of cytokine
expression as well as modulation of y-secretase activity (Weggen et al.

003 ). Some

NSAIDs are known to be PPAR-y agonists, modulating oxidative stress and inhibiting of
expression of inflammatory genes (Lehmann et al., 1997; Landretl- and Heneka, 2001;
McNaull et al., 2010). However, a number of studies using role >xib (Reines et al.,
2004), naproxen (Aisen et al., 200.3), diclofenac (Scharf et al., 1999), celecoxib (Soininen
et al., 2007), dapsone (Eriksen et al.. 2003), hydroxychloroquine (Aisen et al., 2001) and
nimesulide (Aisen et al., 2002) failed to slow progression of cognitive decline in patients
with mild to moderate AD. A number of factors may be responsible for the failure or
disappointing results in the clinical studies involving the use ofNSAIDs. These include
inadequate drug penetration into the brain, inadequate doses and the variability in
diagnosis and progression of AD in individuals (Rojo et al., 2008). Indeed a very recent
study indicates that prolonged use ofNSAIDs decreases the incidence of AD when taken
by only asymptomatic individuals (Breitner et al., 2011). This suggests that timing of
anti-inflammatory use is critically important when considering any therapeutic strategies
for AD.
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Structure, function and inhibition of Src family of tyrosine kinases
I yrosine kinases are enzymes that catalyze the transfer of phosphate groups from
ATP to the tyrosine residues within proteins. Tyrosine kinases are part of the larger
family of protein kinases. Proteins that become phosphorylated by tyrosine kinases, or by
other kinases, allow for the signal transduction pathways that regulate many o f the
functions of cells. The Src family of tyrosine kinases (STKs) is a non-receptor kinase
family with nine members: Lyn, Fyn, Lck, Hck, Fgr, Blk, Yrk, Yes and c-Src. c-Src
(henceforth referred to a Src) is the best studied non-receptor tyrosine kinase and is
commonly implicated in oncogenesis (Yeatman, 2004), cellular proliferation, survival,
migration, and angiogenesis (Hanahan and Weinberg, 2000; Yeatman, 2004).
Proteins in the Src family have a conserved organization consisting of four Src
homology (SIT) domains and a C-terminal segment containing a negative regulatory
tyrosine residue (Tyr530) (Fig. 4). Src exists in both active and inactive conformations.
Negative regulation occurs through phosphorylation of Tyr530, resulting in an
intramolecular association between phosphorylated Tyr530 and the SH2 domain of Src,
thereby locking the protein in a closed conformation. Further stabilization of the inactive
state occurs through interactions between the SH3 domain and a proline-rich stretch of
residues within the kinase domain (Sicheri and Kuriyan, 1997). Conversely,
dephosphorylation of Tyr530 allows Src to assume an open conformation (Aleshin and
Finn, 2010). Full activity requires additional autophosphorylation of the Tyr419 residue
within the catalytic domain (Lowell, 2004). The intramolecular activity of Src is
regulated by a balance between kinases and phosphatases including other receptor
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tyrosine kinases such as epidermal growth factor receptor (EGFR), fibroblast growth
factor receptor (FGFR) and platelet-derived growth factor receptor (PDGFR) as well as
direct binding of Focal Adhesion Kinases (FAK), that mainly act at the C-terminal
Tyr530 residue (Sakai et al., 1994; Parsons and Parsons, 1997).
Y419

Negative
regulation

Src inactivation

Recognition

Integrins (Src activation)

Y530

Kinase
(catalytic domain)

Receptor Tyrosine kinase

Figure 4. Src activation and inactivation (adapted and modified from (Aleshin and
Finn, 2010) and (Tatosyan and Mizenina, 2000)
As mentioned. Src activation is an important event in various cell processes in
normal and malignant cells. Src plays a key role in regulation of cell adhesion and
migration. Dynamic turnover of cell-cell (adherence junctions) and cell-matrix (focal
adhesions) junctions is crucial for normal cellular adhesion, migration, and division
(Biscardi et al., 1999; Playford and Schaller, 2004; Yeatman, 2004; McLean et al., 2005;
13

Guarino, 2010). The subcellular localization of Src is critical to its function of regulating
the assembly and disassembly of these junctions. An increase in Src signaling deregulates
cell-cell adhesion. In association with FAK, Src mediates signals from extracellular
matrix-integrin complexes to the cell interior, thereby influencing cell motility, survival,
and proliferation (Roche et al., 1995; Prathapam et al., 2006). Src is also suggested to be
involved in regulating cell cycle progression and mitogenesis (Weng et al., 1994; Roche
et al., 1995; Prathapam et al., 2006). Src activation is associated with increased
expression of proangiogenic cytokines such as VEGF and interleukin 8 (IL-8) (Kanda et
al., 2007). Treatment with 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]
pyrimidine (PP2), a potent and selective inhibitor of SFKs, inhibits angiogenesis in vivo
and blocks endothelial cell differentiation in vitro (Kilarski et al., 2003). Inhibiting Src
blocks lL-8-mediated VEGFR2 activation and decreases vascular permeability (Yeh et
al., 2004; Petreaca et al., 2007). Furthermore, SFKs are implicated in endothelial cell
function, with inhibition of Src, Fyn, and Yes decreasing VEGF-induced endothelial cell
migration (Werdich and Penn, 2005).
The Src family of tyrosine kinases has been identified as important for
recruitment and activation of immune cells like monocytes, macrophages and neutrophils
into pro-inflammatory sites. Several Src family members, Blk,Fgr, Hck, Lck, Lyn and
Yes have been implicated in signaling responses in hematopoetic lineage cells (De
Franceschi et ah, 1997; Lowell and Berton, 1999; Gardai et ah, 2002; Nijhuis et ah, 2002;
Rane and Reddy, 2002). Src family members, Lck and Fyn are expressed in T-cells and
are known to become activated directly downstream o f the T-cell receptors (Barber et ah,
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1989). Macrophage and monocytes have been reported to express Fyn. Yes, Src, Hck and
Lyn kinase (Okutani et al., 2006). LPS stimulation increases the expression of Hck in
monocytes, human peripheral blood monocyte-derived macrophages and murine-bone
marrow derived macrophages (Ziegler et al., 1988; Boulet et al., 1992; Beaty et al., 1994;
Cohen, 2002). Lyn expression and activity is also increased in LPS stimulated
macrophage and monocytes (Ziegler et al., 1988; Boulet et al., 1992; Beaty et ah, 1994).
Blocking tyrosine kinase activity also reduces low-dose LPS induced TNF-a production
as well as LPS-induced NF-kB translocation in macrophage (Khadaroo et ah, 2003;
Khadaroo et ah, 2004). LPS stimulation recruits Src protein tyrosine kinases into the LPS
receptor complex via CD 14 (Stefanova et ah, 1993). Other pro-inflammatory mediators
have also been reported to be associated with Src family members, besides LPS. Src
protein tyrosine kinases bind to IL-6 receptor b-chain, gpl 30 in macrophage (Schaeffer et
ah, 2001). In addition to the involvement in pro-inflammatory pathways, Src kinases play
critical roles in other cellular functions o f macrophage. Src kinases arc known to
associate with integrin heterodimers that play important role in migration and adhesion of
macrophage (Suen et ah. 1999; Caveggion et ah, 2003). Macrophage with Src family
kinases knockdown display alterations in cytoskeleton dynamics and polarization.
Abundant evidence of pharmacological intervention against Src protein tyrosine
kinase in acute inflammation responses has been reported in vivo. Use of the selective Src
kinase inhibitor PP1 in brain injury models in rats has been shown to reduce brain edema
and mortality as well as suppressed vascular permeability in a mouse model o f stroke
(Paul et ah, 2001; Lusaka et ah, 2004; Lennmyr et ah, 2004). Another Src kinase
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inhibitor PP2. reduces alveolar macrophage priming in an acute lung injury model (Aid)
in vivo (Khadaroo et al., 2004). Decreased LPS-induced acute lung injury and LPSinduced mortality were reported with PP2 injections as well (Severgnini et al., 2005).
With a key role in cell proliferation, invasion and metastasis, Src has been
identified as a major target for therapeutic intervention with various Src inhibitors being
identified for clinical purposes. One o f the most studied Src inhibitors finds relevance in
our study as well. Dasatinib, commercially available as Sprycel (Bristol-Myers Squibb) is
an FDA approved drug for Chronic Myelogenous Leukemia. Dasatinib is an orally
available, small-molecule Src/Abl inhibitor that has robust antitumor and antiproliferative
activity against numerous hematologic and solid tumor cell lines (Lombardo et al., 2004;
Das et al., 2006; Chang et al., 2008). In addition to inhibiting Src and Bcr-Abl in the
subnanomolar range, dasatinib also variably inhibits other SFKs, c-KIT, PDGFR, and
ephrin A2 (Chang et al., 2008). The mechanism o f Src inhibition results from a hydrogen
bond-mediated association with the ATP binding site, resulting in competitive restriction
of ATP binding by Src (Lombardo et al., 2004). This compound emerged from a series of
Lck inhibitors originally synthesized as anti-inflammatory compounds. Dasatinib (BMS354825) is potent against cAbl and BCR-Abl, inhibiting the pure enzyme with an 1C50 of
<1 nM(Jakubowska and Czyz, 2006). According to the Cancer Drug Information,
National Cancer Institute, due to the activity of dasatinib against BCR-AbL especially its
activity against mutant forms of BCR-Abl that are resistant to Gleevee treatment, BristolMyers developed this compound as a therapy against CML and ALL in pre-clinical and
clinicai trials. As shown in vitro, Dasatinib was effective on patients harboring mutations
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resistant to Gleevec but not in those patients whose CML cells contained mutation T 3 151.
This mutant proved to be resistant to Dasatinib in vitro (Quintas-Cardama et al., 2007).
These results led to FDA approval of dasatinib for Cdeevec-resistant CML in June 2006
at a recommended dose for CML(Gnoni et ah, 2011). Dasatinib is also known to cross the
blood brain barrier, although the efficiency of the transport is not yet known (Porkka et
ah, 2008).
During microglia stimulation, tyrosine phosphoi-ylation systems have been found
to be particularly activated in vitro and in vivo (Tillotson and Wood, 1989b). Elevated
protein phosphotyrosine levels have been reported, selectively in ramified microglia
(Wood and Zinsmeister, 1991). Tyrosine phosphorylation of a variety of substrates is
quantitatively enriched in microglia compared to other neural cel! types. Therefore,
protein tyrosine kinases have been seen as reliable markers for microglial activation in
Alzheimer’s disease (Karp et ah, 1994). In vitro studies using monocytic lineage cells
(Combs et ah, 1999) as well as microglia (Sondag et ah, 2009) have supported these data
by demonstrating that A(3 fibrils and oligomers stimulate a specific increase in overall
protein tyrosine phosphorylation. This supports the idea that tyrosine kinase inhibition
may be useful for attenuating microgliosis in AD.
Hypothesis
Microglial-dependent proinflammatory changes are a component of Alzheimer’s
disease process suggesting that strategies to limit acquisition of a reactive phenotype may
be therapeutically useful. However, in order to modulate microglial behavior during
disease it is necessary to understand their source of stimulation and the resultant
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mechanism of activation. One possibility is that AfS peptide in both its fibrillar and
oligomeric form may activate microglia during disease. As already mentioned, prior work
from our lab as well as others has demonstrated the ability of fibrillar peptide to stimulate
microglia. Prior work has shown that the oligomeric peptide is a potent proinilammatory
stimulus also utilizing tyrosine kinase mechanism (Sondag el al., 2009). This increase in
tyrosine kinase activity is required for subsequent secretion of the neurotoxic cytokine,
TNFa. Ap oligomers were also shown to be toxic to cultured neurons only in the
presence of microglia (Sondag et ah, 2009).
Therefore, targeting Ap oligomer and fibril dependent signaling mechanism in
microglia, especially those including the Src family of kinases, presents a therapeutically
attractive target to attenuate microgliosis in AD. This work aims to indentify Src kinase
inhibitory properties of a commercially available cancer drug, dasatinib as well as
characterizing novel Src kinase inhibitors, for attenuating Ap oligomer and fibril
dependent microgliosis in various disease models including primary microglia cultures,
AP infused in vivo models and a transgenic mouse model of AD.
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CHAPTER 2
METHODS
Materials
Anti-oligomer antibody (111) and anti-fibril antibody (O.C.) have been previously
described (Kayed et al., 2007). The anti-oligomer antibody ( Al l ) was purchased from
Invitrogen (Camarillo, CA). Anti-Ap, clones 6E10 and 4G8 were from Covance
(Emeryville, CA). The anti-Lyn antibody, anti-Src, anti-a-tubulin antibodies and
horseradish peroxidase conjugated secondary antibodies were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA). Mouse TNF-a ELISA kit was obtained from R&D
Systems (Minneapolis, MN). Anti-phospho-tyrosine (4G10) antibody was from Upstate
(Temecula, CA), HLA-DR Ab-1 (LN3) antibody was from Neomarkers (Fremont, CA)
and anti-pLyn (396) antibody was purchased from Abeam (Cambridge, MA). Anti-CD68
was obtained from Serotec (Raleigh, NC). Anti-APP antibody was purchased from
Invitrogen (Camarillo, CA). The non-receptor tyrosine kinase inhibitor, dasatinib, was
obtained from LC Laboratories (Woburn, MA). Elite Vectastain ABC avidin and biotin,
biotinylated anti-rabbit, anti-mouse, anti-rat antibodies and the Vector VIP chromogen
kits were from Vector Laboratories Inc. (Burlingame, CA). -\nti-PSD95 and anli-pSrc
(1 yr 416) antibody was purchased from Cell Signaling Technology (Danvers, MA). Antisynaptophysin and anti-pill tubulin antibodies were purchased from C-hemicon
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International, Inc (Temecula, CA, USA). The transgenic mouse line, strain 005864
B6.Cg-Tg(APPswe,PSEN ldE9)85Dbo/J and wild-type mouse line, C57BL/6J were
obtained from the Jackson Laboratory (Bar Habor, Maine).
Animal Use
All animal use was approved by compliance with the University of North Dakota
Institutional Animal Care and Use Committee (UND IACUC). Mice were provided food
and water ad libitum and housed in a 12 h light/dark cycle. The investigation conforms to
the National Research Council of the National Academies Guide for the Care and Use of
Laboratory Animals (8th edition).
Human Tissue
Human AD and age-matched control tissue was obtained from the
University of Washington Alzheimer’s Disease Research Center, Grant # P50AG05136
and University of Iowa Brain Bank. The investigation conforms to the principles outlined
in the Declaration of Helsinki. All human tissue use was approved by the University of
North Dakota Institutional Biosafety Committce/lnstitutional Review Board.
Preparation o f Peptides
A p t-42 was purchased from Bachem (Torrance, CA) or American Peptide
(Sunnyvale, CA) for fibril and oligomer preparations, respectively. Api-42 pepliu.
dissolved in 1:1 acetonitrile-water, aliquoted and dried. The aliquoted peptides were
stored a t-20 degree C until use. For oligomer preparation, each tube was dissolved in 50
pL HFIP and then diluted with 175 pL of sterile water and stirred at room temperature
for 48h. The peptide was then spun at 14,000 rpm, for 10 min and the supernatant
quantified using the method of Bradford (Bradford, 1976). For Ap fibril preparations.
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Api-42 peptide was dissolved in deionized water and incubated for a week at 37 degrees
C. Before use, the fibril was mixed well and quantified using the Bradford assay.
Structural Peptide Analyses
For Western blot analysis of SDS-stable multimeric forms of oligomers, the
peptide was diluted to different concentrations, separated by 15% SDS-PAGE and
analyzed by Western blot using 6E10 (anti-AP) as the primary antibody. For dot-blot
analyses of oligomers and fibrils, lpg each o f Ap oligomer or fibril were dot blotted onto
polyvinylidene fiouride (PVDF) membrane and incubated with A 11 (anti-oligomer) and
6E10 (anti-AP) antibodies and analyzed via enhanced chemiluminescence (GE
Healthcare, Piscataway, NJ).
BV2 Cell Line
Immortalized murine microglial BV2 cells were obtain 1 from Dr. Gary E.
Landreth, Cleveland, Ohio. The cells were

amed at 3 x I0h cells/dish in 100-mm

dishes in DM EM /FP fGibco RBL, Rockville, MD) supplemented with 10% heatinactivated FBS (U.S. Biotechnologies Inc., Parkerford, PA). 5% horse serum (EquitechBio, Inc., Kerrville, TX), penicillin G (100 units/ml), streptomycin (100 mg/ral), and 1glutamine (2 niM) and incubated at 37 °C in a humidified atmosphere containing 5% CO t
and 95% air.
Tissue Culture
Microglia cultures were derived from the brains of postnatal day 1-3 C57BL/6J
mice (Floden and Combs, 2006). Briefly, cortices were removed and trypsinized. The
trypsin was inactivated in microglial growth media (DMEM/F-12 with L-glutamine
(Invitrogen) containing 10% heat-inactivated FBS, 5% heat-inactivated horse serum, and
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antibiotics, penicillin, streptomycin and neomycin (Gibco, Invitrogen). The tissue was
triturated and plated into tissue culture flasks. After 24 hours all media and cellular debris
was replaced with fresh media. After 7 more days one half o f the media was replaced and
cells were maintained as a mixed glia culture until day 14. At 14 days in vitro, microglia
were shaken from the mixed glial culture at 200 rpm for 45 min and collected for use.
Cell Stimulation
BV2 cells and/or microglia were placed into serum-free DMEM/F12 media for
stimulations with A|3 oligomers or fibrils. To inhibit tyrosine kinases, cells were
pretreated with drug or vehicle (DMSO) for 30 min before adding the appropriate
concentrations of peptides. For ELISA analysis, cells were stimulated in 96-well plates
(20,000 cells/ well, 75 pL serum-free DMEM/F12) for 24 hours with 8 replicates per
condition repeated 4-5 independent times. Experiments for Western blot analyses were
performed for 5 minutes to assess signaling changes. After stimulation, cells were lysed
in RIPA buffer (20mM Tris. pH 7.4, 150mM NaCl, ImM Na^VCE lOmM NaF, ImM
EDTA, ImM EGTA, 0.2mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 0.1%
SDS, and 0.5% deoxycholate) with protease inhibitors (AEBSF 104mM, Aprotinin
0.08mM, Leupeptin 2.ImM, Bestatin 3.6mM, Pepstatin A 1.5mM, E-64mM). Protein
concentrations were determined using the Bradford method (Bradford, 1976). For toxicity
analyses, cells stimulated for 24 hours were used for MTT reduction toxicity assay.
Enzyme Linked-immuno-sorbent Assay (ELISA)
Media was collected from microglia following 24 hour stimulation for ELISA
analysis. Levels o f mouse TNF-a in the media were determined using commercially
available ELISA kits according to the manufacturer’s protocol (R&D Systems).
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Cell Viability Assay
The MTT reduction assay was performed to assess changes in cell survival. In brief,
the media was removed from cells stimulated with or without A|3 and dasatinib and
replaced with media containing 3[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium
bromide (MTT, lOOpg/mL) for 4 hours. The media was aspirated and the reduced
formazan precipitate was dissolved in isopropanol and absorbances read at 560/650nm
via plate reader and averaged. For the Lactate Dehydrogenase Release (LDH) Assay,
media was collected following 24 hour cell stimulation and centrifuged (14,000xg, 2 min,
25°C). Aliquots were then added to a 96-well plate and LDH concentrations assayed
according to manufacturer’s instructions (Promega Corporation, Madison, WI).
Background absorbance was subtracted from each condition. Values were averaged (±
SD).
Western Blot Analysis ofB V2 Cells and Microglia Cultures
Cell lysates from 5 minute stimulations were resolved by SDS-PAGE and
transferred to PVDF membranes. Western blots were blocked and incubated in antiphospho-tyrosine (4G10), anti-pSrc (Tyr 416) and anti-pLyn (Tyr 396) as primary
antibodies with a-tubulin, Src and Lyn antibodies as the respective loading controls.
Blots were washed followed by incubation with HRP-conjugated secondary antibodies
and antibody binding was detected via enhanced chemiluminescence (GE Healthcare,
Piscataway, NJ).
Intracerebroventricular Infusion o f Ap 1-42 Oligomers and Dasatinib
A|3 oligomers with or without dasatinib were infused into the right ventricle of
C57BL/6 female mouse brains at 12 months of age. Mice were anesthetized with sodium
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pentobarbital (Nembutal, 70mg/kg) and a scalp incision made for stereotaxic placement
of the cannula. Blunt end dissection caudally from the base of the scalp incision were
performed to generate a small subcutaneous pocket for placement of an Alzet (model
1004, 0.25pL/hour delivery rate, Cupertino, CA) osmotic pump in the sub-scapular
region. A cannula (Brain infusion kit, Alzet) was stereotaxically placed into the right
lateral cerebral ventricle at coordinates —1.0 mm mediolateral and -0.5 mm
anterioposterior from EiCgma: -1.5 mm dorsal-ventral from skull. The cannulae were
connected to subscapularly placed miniosmotic pumps (Alzet, model 1004) delivering
either A|3 oligomers (1.6pg/day) or vehicle (4mM Hepes, 250pg/mL human high density
lipoprotein) with or without dasatinib (500ng/kg/day) for 14 days. At the end of the
infusion period, mice were euthanized, brains perfused with PBS-CaCf> and rapidly
collected. The right hemispheres were collected for cryosectioning and the left
hemispheres were flash frozen in liquid nitrogen and lysed in RIPA buffer for
biochemical analysis.
Collection o f Brains from Different Age APP/PS1 Mice
Brains from different aged APP/PS1 mice were collected for longitudinal
analyses. 2, 4, 6 and 12 month old transgenic mice (n=5-6) along with their age-matched
C57BL/6 wild type controls were euthanized and perfused with PBS-CaCB. Brains were
rapidly dissected and divided into left and right hemispheres, with right hemispheres
fixed in 4% paraformaldehyde for sectioning. The left hemispheres were further dissected
into different brain regions to obtain hippocampus, temporal cortex, frontal cortex and
cerebellum and flash frozen using liquid N2. The frozen tissue was lysed using RIPA with
protease inhibitor and quantified by the method of Bradford.
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Subcutaneous Infusions o f Dasatinib into APP/PS1 mice
Dasatinib was infused subcutaneously into female APP/PS1 mice at 13 months of
age. Dasatinib was delivered via mini-osmotic pumps (model 1004. 0.25pL/hour delivery
rate, Alzet, Cupertino, CA). Pumps delivered either vehicle (DMSO/Hepes) (n=6) or
dasatinib (500ng/kg/day) (n=7) for 28 days. At the end of the infusion period, mice were
euthanized, brains perfused with PBS-CaCh, and rapidly collected. The right
hemispheres were collected for fixing in 4% paraformaldehyde and the left hemispheres
were flash frozen in liquid nitrogen for biochemical analysis.
Immunostaining Mouse Brains
The paraformaldehyde fixed right hemispheres for different age mice or from
dasatinib treated mice were sectioned using a freezing microtome. Briefly,
paraformaldehyde fixed tissue was embedded in a 15% gelatin (in 0 . 1 M phosphate
buffer) matrix and immersed in a 4% paraformaldehyde solution for 2 days to harden the
gelatin matrix. The blocks were then cryoprotected through 3 cycles of 30% sucrose for
3-4 days each. The blocks were then flash frozen using dry-ice/isomethylpentane, and
serial sections (40pm) were obtained using a freezing microtome. Serial sections were
used for immunostaining with anti- pTyr (4G10) antibody at a dilution of 1:1000. anti-A(3
(4G8) and anti-CD 68 at a dilution o f 1:500, anti-pSrc as 1:250. anti-GFAP antibody at a
dilution of 1:1000, anti-Al 1 antibody at 1:250, O.C. antibody at 1:4000, and anti-111
antibody at a dilution of 1:500 followed by incubation with biotinylated secondary
antibodies (1:2000 dilution) (Vector laboratories Inc. Burlingame, CA) and avidin/biotin
solution (Vector ABC kit). Immunoreactivity was visualized using visible light
chromogens VIP, Vector Blue, and DAB (Vector Laboratories). The slides were
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dehydrated and cover slipped using VectaMount (Vector Laboratories) following a
standard dehydrating procedure through a series o f ethanol solutions and Histo-Clear
(National Diagnostics, Atlanta, GA). Images were taken using an upright Leica DM1000
microscope and Leica DF320 digital camera system. Figures were made using Adobe
Photoshop 7.0 software. For quantitation purposes, 1.25X images were taken from 3
consecutive serial sections, (960pm apart) throughout the hippocampal region. Optical
densities from the temporal cortex and CA1 regions from the same serial sections were
measured using Adobe 1 otoshop software (Adobe Systems, San Jose, CA). All sections
were immunostained at the same time to minimize background variability and
background values in an unstained area of tissue for each section was set to zero using the
curve tool before measuring optical density values. The optical density o f the entire
temporal cortex region/CAl region from a representative section was selected via
marquee. The same size marquee was applied to all sections across all conditions to allow
comparison of optical densities independent of area changes. The values for each section
were averaged (3sections/brain, 5-7 brains per condition) and plotted for A(3,
immunoreactivity for dasatinib infusion animals and A|3 and CD 68 immunoreactivities
for longitudinal study animals. For quantitating phosphotyrosine immunostaining for
different aged APP/PS1 and wild type mice, the serial sections were viewed under a
microscope and the number of 4G10 positive plaques were counted from the entire CA1
and temporal cortex regions for all the animals in each condition. The numbers of plaques
were averaged (3 sections/brain, 5-7 brains per condition) and plotted.
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Double Label Immunofluorescence
For double label immunofluorescence staining, tissue was incubated in the desired
primary antibodies and then corresponding Texas red and FITC-conjugated secondary
antibodies (Santa Cruz Biotechnology, Santa Cruz, CA). Tissue was counterstained with
DAPJ and visualized using a Zeiss LSM-510 META Confocal Microscope (Thornwood,
NY).
Western Blot Analyses o f Mouse Brains
Hippocampus and temporal cortex were removed from flash frozen brains of
treated mice, lysed, sonicated in RIPA buffer, and quantitated using the Bradford method
(Bradford, 1976). The lysates were resolved using a custom-built 28-well comb and 10%
SDS-PAGE and transferred to polyvinylidene di fluoride membranes for Western blotting
using anti-pTyr (4G10), anti-APP, anti-Aff (6E10), anti-GFAP, anti-TNF-a and antiCD 68 antibodies with a-tubulin as their loading control, anli-pSre (Tyr416), anti-pLyn
(Tyr 396) antibodies with anti-Src and anti-Lyn as their respective loading controls and
anti-PSD95 and anti-synaptophysin with pill-tubulin as the loading control. Antibody
binding was detected using enhanced chemiluminescence. Western blots were quantified
using Adobe Photoshop software. Optical density (O.D.) of bands were normalized
against their respective loading controls and averaged (+/-SEM).
Thioflavin Staining
Mouse brain sections from Ap oligomer and vehicle infused animals were stained
with thioflavin (O.lg/lOmL) and counterstained with 4,6-diamidino-2-phenylindole
(DAPI) (Invitrogen) to visualize the nucleus. To quench lipofuscin autofluorescence, the
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sections were then incubated in 0.1% Sudan Black for 30 min, rinsed with PBS and cover
slipped using PBS-glycerol ( 1 : 1 ).
Human Tissue Double Staining
Human tissue was obtained from University o f Washington Alzheimer
Disease Research Center (ADRC, NIH P50AG05136) and was sectioned via freezing
microtome (40pm) for immunostaining using DAB or Vector Red (Vector Laboratories,
Burlingame, CA, US) as the first chromogen. The sections were then stripped using 0.2N
HC1, 5 min. and incubated with the second primary antibody for immunostaining using
Vector Blue or Vector SG (Vector Laboratories) as the second chromogen.
Dmaze
T-maze analysis was performed as described preciously (Wenk. 1998). Briefly,
upon completion of the in vivo infusion period mice were placed into the starting arm.
and the door was raised to allow animals to walk down the stem and choose an arm. Once
the mice entered an arm with all four feet, they were returned to the starting arm and the
door was closed. After 30 sec, the door was opened and the mice were allowed to choose
an arm again. The process was repeated for 9 trials with a 30 sec interval between each
trial. The choice of arms was noted each time and the number of alternations between
trials for each mouse was averaged and plotted.
Dot Blot
To obtain a dose response curve for the LDDN drugs on BV2 cells, the cells were
untreated (control), vehicle-treated, or treated with 0.0005 pM, 0.005 pM. 0.05 pM. 0.5
pM, 5 pM and 50 pM of the drug for 30 minutes. The cells were then lysed in RIP A
containing protease inhibitor and Bradford quantified. Lysates were diluted with 3X

28

sample buffer, boiled, and stored in -20° for use. For dot blot analyses, PVDF membranes
were prepared by first incubating in methanol solution for 5 minutes, and then soaking in
Tris-Glycine solution for 10 minutes. The membranes were then placed into a dot blot
apparatus and the apparatus was closed to create an air-tight seal for the vacuum to work.
Using a narrow-mouth pipet, 2 microgram of lysate was blotted onto each well. After the
loading was complete, the vacuum pump was turned on for 30sec-lmin, to make sure all
the solution was pulled through the membrane allowing protein to adhere. The
membranes were then blocked in 3%BSA solution and incubated in anti-pTyr (4G10),
anti-pLyn, anti-pSrc and anti-pERK antibodies with u-tubulin, Lyn, Src and ERK2
antibodies as loading controls overnight at 4°C. Blots were rinsed the next day and
incubate in secondary antibodies and detected with enhanced chemiluminescence (GE
Healthcare). Dot blots were quantified using Adobe Photoshop software. Optical
densities of bands were normalized using appropriate loading controls and averaged (+/-)
SD.
Statistical Analysis
Data are presented as mean +/—standard deviation. Values statistically different
from controls were determined using one-way ANOVA. The Turkey-Kravner multiple
comparisons post test was used to determine p values.

29

CHAPTER 3
OLIGOMERIC Ap STIMULATES MICROGLIA THROUGH A TYROSINE KINASE
MECHANISM
Afi0 oligomer stimulated increased total protein phospho-tyrosine levels in primary
microglia cultures that were attenuated by a non-receptor tyrosine kinase inhibitor,
dasatinib.
In order to characterize the form o f A(3 oligomer used in our studies, we first
performed a structural analyses o f the prepared peptide. Preparations were separated via
15% SDS-PAGE to demonstrate that the major detergent resistant multimer of Ap
migrated with an apparent molecular weight loosely correlating with a trimeric/tetrameric
form of the peptide that was stable even after incubation at 37 degree C (Fig. 5A). Larger
amounts of loaded peptide demonstrated larger molecular weight multimers that were
lesser species (Fig. 5A). This low molecular weight migration pattern correlates
approximately with the multimeric confirmations of Ap oligomers isolated from human
cerebral cortex as well as cerebrospinal fluid in which dimer/trimer forms o f Ap have
been the primary forms observed (Klyubin et al.J 2008; Shankar et al., 2008; Villemagne
et al., 2010; Shankar et al., 201 1 ). This demonstrates that several detergent resistant
species of oligomers are present in our preparation validating their use for subsequent
cellular stimulations. In order to further confirm that the peptides were in a stable
oligomeric conformation, dot blot analyses were performed after a period o f 48h at 37
degree C. Oligomeric peptides were compared to fibrillar peptide. As expected, both
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fibrils and oligomers were immunodetected with an anti-Ap antibody 6EI0 (Fig. 5B).
However, only the oligomeric preparation was detected by the anti-oligomer antibody
A 11 (Kayed et af., 2003) (Fig. 5B).
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Figure 5. Structural characterization of A(H-42 oligomers (AfJ„) and Ap

2 fibrils

(APf). The peptide (A) A()„ was prepared and stored overnight at 4 or 37 degree C to
assess multimer stability. Increasing concentrations o f peptide were separated by 15%
SDS-PAGE and Western blotted with anti-Ap antibody, 6EI0. (B) Alternatively,
prepared Apo and Apf were dot blotted ( I jig each) onto PVDF and incubated with anti-Ap
antibody, 6E10. or anti-oligomer antibody. Al l . Arrows indicate border between
stacking and resolving gels for 6E10 Western blots.
We next determined the appropriate concentration of Apo for stimulating
microglia. Our prior studies demonstrated that oligomeric peptide was sufficient to
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increase primary murine microglia total protein phospho-tyrosine levels although the
concentrations employed were above the physiologic range and included a larger range o f
multimeric species in the preparation (Sondag et al., 2009). Primary murine microglia
cultures were treated with varying concentrations o f Aft,, for 5 minutes in order to assess
the signaling response stimulated by peptide interaction. Oligomeric peptide stimulated
an increase in total protein phospho-tyrosine levels (Fig. 6A) that was significantly
different from controls even as low as lOOnM (Fig. 6 B). Importantly this concentration is
similar to that reported from human CSF and human cell culture conditioned medium
(Seubert et al., 1992; Podlisny et al., 1995).
Because different proteins are recognized with anti-phospho-tyrosine antibodies,
it is very common to see different overall Western blot banding patterns with different
concentrations of ligands and different time courses of stimulation since protein
phosphorylation/dephosphorylation is dynamically regulated during all o f the signaling
events initiated during any acute stimulation. Indeed, as can be seen from Figure 6, some
phospho-tyrosine immunoreactive bands steadily increase with dosage while others
demonstrate a biphasic response. To further validate this point, we examined the changes
of two specific tyrosine kinases in these experiments. The non-receptor tyrosine kinase.
Src, was elevated in its active, phosphorylated form at lOOnM Ap 0 stimulation, while
there was no change in the levels of active, Lyn kinase levels with either of the Ap« doses
(Fig.6B). Because of this complex dynamic change we focused on the concentration that
provides a maximal change for overall tyrosine phosphorylation rather than any particular
molecular weight species.

32

A

i" 55 -

| a-tubuiin

mynmm
55 — m m # * '
55 —

55 -—

p-Src
Src

## p-Lyn

p-Src

p-Lyn

Normalized O.O.

2.5

o

2.0

1 10
0.5

vehlelo

100 iM

c

tjiM

10 ,.M

A(t0

0.0

*
**

1.4

p -T y r

1.2

Q 1.0

0
■§ 0.8
.0
1 06
1 0.4
0.2

0.0 1
v

A[J

das

Ap+das

Figure 6. Oligomeric Apl-42 stimulated increased microglial protein phosphotyrosine levels that were attenuated by the tyrosine kinase inhibitor, dasatinib. (A)
Primary microglia were vehicle treated (v), or stimulated for 5 min with 0.1 pM, 1pM and
5pM A(3„. Cell lysates were resolved by 10% SDS-PAGE and Western blotted using aniiphospho-Tyr (4G10), anti-pSrc, anti-pLyn antibodies or anti-a-tubulin, anti-Src and antiLyn (loading controls) antibodies. A Representative blot from 5 independent experiments
is shown. (B) Densitometric analyses o f the Western blots was performed normalizing
protein phospho-tyrosine, pSrc and pLyn levels against their respective a-tubulin, Src and
Lyn controls and averaging +/-SD. Percent fold changes in phospho-tyrosine levels were
plotted (*p< 0.05 from vehicle). (C) Primary microglia were stimulated for 5 min with
1 pM Ap 0

or without 30 min pretreatment with 1OOpM dasatinib (d). A

representative Western blot from 3 independent experiments is shown. (D) Densitometrie
analyses of Western blots were performed for protein phosphotyrosine levels normalized
to their respective a-tubulin control (*p<0.05 from vehicle and dasatinib, **p<0.01 from
AP+dasatinib).
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In order to determine whether this AP stimulated inc % ,e in protein phospho-tyrosine
levels could be inhibited pharmacologically, a clinically relevant non-receptor tyrosine
kinase Src/Abl inhibitor, dasatinib, was used to assess its ability to attenuate the oligomer
stimulated change in total protein phospho-tyrosine levels (Shah et al., 2004; Das et al.,
2006) (Fig.6C). As expected, dasatinib pretreatment attenuated the Af3o stimulated
increase in total protein phospho-tyrosine levels (Fig. 6 D). This data indicates that Apo is
able to stimulate increased tyrosine kinase activity in primary murine microglia at
physiologically relevant concentrations and this can be attenuated through the use o f a
non-receptor tyrosine kinase inhibitor, dasatinib.
Af}0 oligomer stimulated increased TNF-a secretion from primary microglia cultures
To assess cell viability in the presence o f oligomeric A|3 for microglia, primary
microglia cultures were treated with different doses o f Apo. The cells were then used for
MTT assay to determine the toxicity levels. lOpM Apo proved to be toxic to the cells as
compared to control and vehicle treated microglia (Fig 7A). In order to determine
whether the increase in tyrosine kinase activity was responsible for a change in secretory
phenotype, microglia were stimulated with AP oligomers and fibrils with or without
increasing concentrations of dasatinib for 24 hours. A concentration of lpM APo was
used for the stimulations based upon the fact that a robust stimulatory change in protein
phospho-tyrosine levels was observed with this concentration (Fig. 6A) as well as the
toxicity data from MTT analyses o f microglia cells (Fig. 7A). Both fibrillar and
oligomeric AP stimulated a significant increase in TNF-a secretion that was attenuated in
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a dose dependent fashion (Fig. 7B). Since dasatinib attenuated TNF-a secretion
maximally at the lowest concentration employed, lOOpM, this suggests that the drug
concentration curve employed was already above the IC 50 (Johnson et al., 2005). This
data demonstrated that oligomer Ap stimulated a proinflammatory cytokine secretory
phenotype that was dependent upon propagation o f the tyrosine-kinase based signaling
response. The cell viability MTT reduction assay demonstrated that neither the peptide
nor drug treatments were toxic to the microglia (Fig. 1C).
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*ure 7. Oligomeric A01-42 stimulated increased microglial secretion of the
^inflammatory cytokine, TNF-a, that was attenuated by dasatinib. (A) Primary
:voglia were untreated (control), vehicle treated, or stimulated with IpM and lOpM
o for 24 hr to assess cell viability using the MTT assay. Absorbance values
i0/650nm) were averaged+/-SD. (*p<0.05 from vehicle). (B) Primary microglia were
stimulated (control), DMSO vehicle treated (v), or stimulated for 24 hours with 1uM
o or lOpM Apfin the presence/absence of lOOpM, InM and lOnM dasatinib. Media
5 collected from treated cells and used to quantify changes in TNF-a secretion via
ISA. Secreted values were averaged +/-SD (*p< 0.05 from control and vehicle). (C)
er media removal, the treated cells were used to assess cell viability via the MTT
uction assay. Absorbance values (560/650nm) were averaged+/-SD.
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A/i„ oligomers stimulated tyrosine kinase dependent microgliosis in vivo
in order to validate the relevance o f the in vitro findings, we next determined
whether A(30 could stimulate a tyrosine kinase associated microgliosis in vivo. Aj30 was
intracerebroventricularly infused into the right lateral ventricle of 12 month old C57BL/6
mice for 14 days to stimulate gliosis in the absence or presence of co-administered
dasatinib. Aff, infused animals demonstrated a robust increase in microglial-like
phospho-tyrosine immunoreactivity that spatially correlated with increased reactive
microglial CD68 immunoreactivity (Fig.SA). Densitometric analysis of the
immunostaining demonstrated that dasatinib significantly attenuated the A|30-dependent
increase in both phospho-tyrosine (Fig.SB) and CD68 (Fig. 8C) immunoreactivity. To
validate the correlation between increased phosphotyrosine immunoreactivity and
microgliosis, A|3(,-infused tissue was double labeled using anti-phosphotyrosine (4G10)
antibody and CD68 antibody, along with control brain sections. CD68-positive microglia
co-localized with phosphotyrosine immunoreactivity in the Af3-infused mouse brains
(Fig. 8D).
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Figure 8. Intracerebroventrieular infusion of oligomeric Af}l-42 stimulated
increased protein phospho-tyrosinc and CD68 imiminoreactivity that was
attenuated by dasatinib. A[} oligomer (1.2mg/day) or vehicle control (human 11DL in
artificial CSF) in the presence or absence o f drug (500ng/kg/day) were infused into the
right lateral ventricle of 12 month old male C57BI.6/J mice for 14 days (n 6). Brains
39

were fixed, sectioned, and immunostained using anli-phospho-tyrosine (4G10) and CD68
antibodies. (A) Representative images from the dentate gyrus o f the rigiit hippocampus
are shown. The arrow indicates the region imaged for the high magnification insets.
Optical density (O.D.) o f immunoreactivities for (B) phospho-tyrosine and (C) CD68
were quantified from serial sections o f the CA1 region. (*p< 0.001 from c, v, dasatinib
(das) and Ap+dasalinib). (D) Afi oligomer infused brains along with 12-month APP/PS1
and control mouse brains were double-immunostained using anti-phospho-tyrosine, 4G10
(red) and anti-CD68 (green) antibodies and counterstained with DAPI. Images shown are
40x magnification.
In order to compare this acute model of Ap oligomer stimulated increase in
protein phospho-tyrosine immunoreactivity to more chronic gliosis paradigms,
microgliosis in infused brains was compared to that observed in a common transgenic
mouse model o f AD. This particular APP/PS1 model is a double transgenic line that
expresses chimeric mouse/human amyloid precursor protein (Ms/Hu APPswe) and a
mutant human presenilin 1 (PSldE9), allowing the mice to secrete human Ap peptide.
This mouse model o f AD shows a progressive increase in AP deposition with age
(Garcia-Alloza et al., 2006). As expected. CD68 positive microglia in this model but not
C57BL/6J controls correlated with increased phospho-tyrosine immunoreactivity (Fig.
8D). This demonstrated that elevated phosphotyrosine immunoreactivity was a common
presentation of reactive microglia across disease model paradigms including both acute
and transgenic models.
However, it was not clear whether the phospho-tyrosine immunoreactive,
activated microglia in the AP oligomer infused brains correlated with oligomeric AP
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deposition. In order to determine whether microgliosis in the infusion model correlated
with oligomeric Af-i deposits, immunohistochemical analyses o f Ap in infused brains was
performed. Staining with the anti-AP antibody, 4G8, demonstrated immunoreactivity
(Fig. 9A) broadly correlating with the same localization pattern of CD68 and phosphotyrosine immunoreactivity observed in the peptide infused animals (Fig 8A). To
determine whether the infused, immunodetected Apo had remained oligomeric rather
than converting to fibrils, sections o f treated brains were stained using anti-oligomer
antibodies, A 11 and 111 to detect oligomeric species. Both A 11 and 111 antibodies
demonstrated positive immunoreactivity in the Apo infused brains compared to vehicleinfused and control animals (Fig. 9B). This was supported by the fact that Ap<, infused
animals were negative for thiolhvin staining and comparable to the vehicle treated group,
suggesting that the immunodetected AP in infused brains had not fibrillized (Fig. 9C). To
further validate the use o f anti-oligomer antibodies at recognizing non-ftbril
confirmations in situ, again, the transgenic APP/PS1 model was used. Immunostaining of
brains from 12 month old animals demonstrated robust immunoreactivity with anti-fibril
antibody, OC, compared to control animals (Fig. 9D). However, abundant
immunoreactivity o f non-fibril, oligomeric Ap was also observed using Al l , anti
oligomer antibody in these brains. Indeed, although OC and A 11 immunoreactivity colocalizcd to the same plaque structures, each antibody often displayed unique
immunoreactivities within plaques (Fig. 9D). This not only indicates that plaques contain
heterogeneous Ap conformations but also suggests that anti-oligomer antibodies are
useful for immunodetecting peptide conformations in situ, particularly in the infusion
model employed.
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Figure 9. Brains of Aji oligomer-infused animals were thioflavin negative hut
displayed inuminoreactivity with anti-Ap, 4(i8, and anti-oligomer, A! 1 and I11
antibodies. (A) Brains from wild-type control, vehicle-infused, and Aft oligomer-infused
animals (+/-) dasatinib were immunostained with anli-Ap (4G8) antibody. Representative
images from the dentate gyrus o f the right hippocampus are shown. (B) Brains were also
immunostained with anti-oligomer antibodies, A 11 and I I 1, to detect infused peptide.
Representative images o f control, vehicle-infused, and A(3 oligomer-infused animals are
shown, (C) Brains from vehicle-infused and Ap oligomer- infused C57RL/6J mice were
stained with thioflavin to identify the presence of any fibrils and counterstained with
DAP! as a nuclear stain and Sudan black to quench autofluorescence. Representative
images from the dentate gyrus are shown from 6 animals per group. (D) Brains from 12
month old C57BL/6J control and APP/PS1 mice were immunostained with A 11 and OC
antibodies to visualize fibrillar and oligomeric AP peptide deposition. Representative
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double label with A 11 (brown) and OC (blue) is shown. Arrows indicate only A 1 1
immunoreactivity (brown), only OC immunoreacitvity (blue) and co-localization (black).
AD brains demonstrated increased protein phospho-tyrosine, A[l and active Src kinase
levels compared to age matched controls
To further establish the correlation between Ap oligomer levels and tyrosine
kinase dependent microgliosis during disease, we compared human AD tissue with age
matched non-demented controls. As seen in the in vitro and in vivo rodent data,
examination of temporal cortex from human AD brains demonstrated a significant
increase in overall protein phospho-tyrosine levels (Fig. 10A,B). This correlated with a
significant increase is phosphorylated active forms o f the tyrosine kinase, Src, as well as
Lyn kinase, in diseased brains versus their corresponding age- matched controls
suggesting that the protein phospho-tyrosine changes could be related to increased
activity o f the Src family o f kinases (Fig. 10C,D). AD and control tissue lysates were also
analyzed via Western Blot analyses to examine levels of multimeric forms of Ap
oligomers. Densitometric analysis o f the multimeric SDS-stable species (Fig. 5A)
demonstrated that AD brains had a significantly higher level than age-matched controls
(Fig. 10A,B) correlating well with the changes in protein phospho-tyrosine, active Src
and active Lyn levels.
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Figure 10. AD brains had elevated protein phospho-tyrosine, active phospho-Src
and phospho-Lyn levels compared to age-matched controls. AD and age-matched
control (c) temporal lobe lysates (n==6) were resolved by 10% SDS-PAGE and Western
blotted using (A) anti phospho-Tyr (4G10), anti-Ap (6E10), anti-a-tubulin (loading
control) antibodies, (C) anti-Lyn, anti-phospho-Lyn (Tyr396), anti-Src, and antiphospho-Src antibodies. Optical density of (B) Total phospho-Tyr or A(3 multimers and
(D) pLyn and pSrc from 6 AD and age-matched control brain blots were normalized to
their respective a-tubulin blots or total protein Icve's (Lvn/Src) then averaged and
graphed (+/-SD). (*p< 0.001)
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In order to verify whether the changes in protein phospho-tyrosine and AP
oligomers correlated with microglial activation in the AD brains, immunostaining of
fixed AD tissue was compared to age-matched controls. As expected, AD brains
demonstrated defined, plaque-like deposits that were immunoreactive with the anti
oligomer (A 11) antibody (Fig. 11 A). Although A! 1 positive deposits were not uniformly
associated with activated microglia there were clear instances o f HLA-DR (LN3) positive
activated microglia directly associated with oligomeric deposits (Fig. 11A). This
supported the in vitro (Fig. 7) and in vivo (Fig. 8) rodent observations o f the ability of
oligomeric Afi to stimulate microglia and suggested that a similar activation occurs
during disease. To further support the rodent observations, the AD and control brain
sections were immunostained to determine whether HLA-DR positive, reactive microglia
demonstrated increased protein phospho-tyrosine levels indicative o f increased tyrosine
kinase activity. AD brains demonstrated increased immunostaining for reactive microglia
compared to age-matched controls (Fig. 11B). More importantly, reactive HLA-DR
positive microglia co-localized with anti-phospho-tyrosine immunoreactivity in both
diffuse and clustered cell patterns supporting the idea that tyrosine kinase-dependent
changes were a component of the microglial activation process during disease (Fig. 11B).
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Figure 11. A population of AD brain microglia was phospho-tyrosine
inimunoreactive and localized to Aji oligomers. AD and control (c) temporal lobe
sections were immunostained using anti-HLA-DR antibody to identify microglia, anti
oligomer antibody, A 11, to visualize prefibril peptide, and anti-phospho-Tyr (4G10)
antibodies. (A) A 11/HLA-DR double label is shown with (i) only A 11 (red)
immunoreactivity, (ii) double label (black arrow) and (iii) only HLA-DR (grey)
immunoreactivity in the AD brain. (B) A double label for HLA-DR (brown)/phospho-Tyr
(blue) is also shown. Images are representative o f three cases each.

HLA-DR positive microglia from AD brains displayed increased immunoreactivity fo r
active , phosphorylated Src and Lyn kinases.
To begin identifying the specific enzymes responsible for the increased protein
phospho-tyrosine levels, additional immunostaining of activated microglia in AD versus
age-matched control brains was performed. Based upon the Western blot analysis of
increased levels of active phosphorylated Src in AD brains (Fig. 10) immunostaining of
active Src was again compared to the related family member, Lyn. Double label
immunostaining using anti-HLA-DR to identify reactive microglia verified that a
heterogeneous portion of the activated microglia also demonstrated increased
phosphorylated, active Src immunoreactivity compared to age-matched control brains
(Fig. 12A). A small amount of reactive microglia in AD versus control brains also
demonstrated immunoreactivity for phosphorylated active, Lyn (Fig. 12C). The
immunostaining correlated well with the Western blot analysis changes (Fig. 10) and
supported the idea that tyrosine kinase-dependent activation of microglia occurred in AD
brains involving at least the non-receptor kinase, Src. Immunofluorescence and confocal
imaging con firmed the colocalisation o f reacti ve microglia (using HLA-DR antibody)
and active Src immunoreactivity (Fig. 12B) as well as active Lyn immunoreactivity (Fig.
12D)
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Figure 12. A population of AD brain microglia was immunoreactive for phosphoLyn and phospho-Src. AD and control temporal lobe sections were immunostained
using anti-HLA-DR antibody to identify microglia, anti-phospho-Lyn-396 antibody to
identify activated Lyn kinase and anti-phospho-Src antibody to identify activated Src
kinase. (A) p-Src (blue)/I ILA-DR (brown) double label and (C) p-Lyn (grey)ZHLA-DR
(red) double label images are shown. Images are representative of three cases each. AD
and control temporal lobe sections were also double-labeled using immunofluorescence
using (11) anti-HLA-DR (green) and anti-pSrc (red) antibodies or (D) anti-HLA-DR
(green) and anti-pLyn (red) antibodies.
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CHAFFER 4
ROLE OF SRC KINASE IN AMYLOID DEPENDENT MICROGLIOSIS IN AD
Based upon our prior work demonstrating that both fibrillar and oligomeric Ap
stimulate increased non-receptor tyrosine kinase activity in microglia (Sondag et al.,
2009), we determined whether a brain penetrant tyrosine kinase inhibitor, dasatinib, could
attenuate activity of Src kinase in vitro.
The non-receptor tyrosine kinase inhibitor, dasatinib, decreased active-phospho Src
levels in microglia BV2 cells
In order to validate the Src-kinase inhibitory ability of dasatinib, the mouse
microglia cell line, BV2, was treated with varying concentrations of dasatinib. Dasatinib
is a small molecule ATP-competitive inhibitor of BCR/Abl and Src kinase with IC'50s for
the isolated kinases of 0.55 and 3.0 nM, respectively (Lombardo et al., 2004; Nam et al.,
2005). FDA approved for use in cases o f Chronic Phase Philadelphia chromosome
positive Chronic Myelogenous Leukemia (CP-CML), dasatinib (Sprycel, Bristol-Myers
Squibb), has been shown to the cross the blood brain barrier (Porkka et al., 2008). As
expected, active, phosphorylated Src levels significantly decreased with increasing
dasatinib concentrations from InM to 1pM compared to vehicle treated BV2 cells
(Fig. 13). For subsequent treatments o f microglial cells in vitro, a dose o f lOOnM
dasatinib was chosen to obtain an optimum effect of AP-dependent tyrosine kinase
inhibition in primary cultures.
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Figure 13. Dasatinib dose-dependentiy attenuated active, phospho-Src kinase levels
in the BV2 cell line. (A) Microglial BV2 cells were vehicle treated (v), or treated with
InM, 10nM, lOOnM and lpM dasatinib for 30 min. Cells lysates were resolved by SDSPAGE and Western blotted using anti-phospho-Src, and Src antibodies. (B)
Densitometric analyses o f the Western blots were performed normalizing active-pSrc
levels against their respective Src controls and averaging +/-SEM. Blots are
representative of 6 independent experiments.
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Dasatinib attenuated the Aft-stimulated increase in active-phospho Src levels in primary
murine microglia cultures
In order to determine whether dasatinib was able to reduce an Afi stimulated
increase in active tyrosine kinase levels, primary microglia cultures were treated with A(3
fibril with or without dasatinib. Microglial cells were pretreated with lOOnM dasatinib
followed by 5 minute stimulation by 1OpM Af3f to detect changes in the activated,
phosphorylated forms of the specific non-receptor tyrosine kinases, Src and Lyn. As
expected, Aft fibrils stimulated an increase in active-phospho S;c levels compared to
vehicle treated cells (Fig. 14). The Ap-dependent increase in phospho-Src levels was
significantly attenuated when cells where stimulated in the presence o f dasatinib (Fig.
14). Although Aft fibrils did not significantly increase the levels o f active,
phosphorylated Lyn kinase at the concentrations used, dasatinib was still able to
significantly reduce levels o f active phospho-Lyn indicating that the drug wes not
specific to any particular Si family member (Fig 14). In addition, the data demonstrated
that the Ap stimulated increase in microglial active Src kinase levels could be inhibited
using a clinically relevant non-receptor tyrosine kinase Src/Ahl inhibitor, dasatinib.
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Figure 14. Dasatinib attenuated an A|J-stiinulated increase in active, phospho-Src
kinase levels in primary microglia cultures. (A) Primary microglia were vehicle treated
(v,veh), or stimulated for 5 min with lOpM A(h in presence or absence o f 30 min
pretreatment o f lOOnM dasaunib. Ceils lysates were resolved by 10% SDS-PACiR and
Western blotted using anti-pSrc or Src (loading control) antibodies and anti-pLyn or Lyn
(loading control) antibodies. A Representative blot from 6 independent experiments is
shown. (B) Densitometrie analyses o f the Western blots was performed normalizing
active, phospho-Src levels against Src control and active, phospho-Lyn levels against Lyn
control paid averaging +/-SE. Percent fold changes in phospho-Src levels were plotted.
(*p<0.05 vs. vehicle, dasatinib. **p<0.01 vs. Ap+dasatinib for pSrc and *p<0.01 vs. A{1
for pLyn)
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Dasatinib attenuated All-stimulated TNF-a secretion in primary microglia cultures
In order to determine whether the AfKstimulated change in active Src levels was
required for changes in phenotype, changes in secretion o f the pro-inflammatory
cytokine, TNF-a, was quantified from the primary microglia cultures in the presence or
absence o f dasatinib. Fibrillar A (I stimulated a significant increase in TNF-a secretion
compared to control or vehicle treated microglia! cells (Fig. 15). This increase in TNF-a
secretion was attenuated by lOOnM pretreatment o f dasatinib with no effect on cellular
viability (Fig. 15). The data demonstrated that inhibition of Src family kinase activity was
sufficient to prevent microglia from acquiring a reactive secretory phenotype upon AjJ
fibril stimulation in vitro.
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Figure 15. Dasatinih attenuated A(51-42 stimulated-microglial secretion of the
proinflanimatory cytokine, TNF-a. Primary microglia were unstimulated (control),
DMSO vehicle treated (veh), or stimulated for 24 hours with lOpM Apr in the
presenec/abscnce o f lOOnM dasatinib. ( A) Media was collected from treated cells and
used to quantify changes in TNF-a secretion via ELISA. Secreted values were averaged
+/-SE. (It) After media removal, the treated cells were used to assess cell viability via the
MTT reduction assay. Absorbance values (560/650ntn) were averaged+/-SE. (**p< 0.01
from control, ***p<0.()01 vs veh.dasatinib and AjJ+dasatinib).
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An age-dependent increase in Aft plaque density correlated with microgliosis in a
transgenic mouse model o f AD
To determine art appropriate age in vivo for examining increased tyrosine
kinase activity and Aji-associated microgliosis, a transgenic APP/PSl mouse mode! of
AD was used. Brains o f varying aged APP/PSl mice were compared to age-matched
controls to validate the use o f this transgenic mouse model for our study. The APP/PSl
mice were collected at 2 ,4 ,6 and 12 months o f age along with their age-matched wild
type (C57BL/6) mice and brains were sectioned for histology. Immunostaining
demonstrated a significant increase in APP/PSl temporal cortex CD68 immunoreactivity
in 6 and 12 month old mice compared to the earlier 2 and 4 month APP/PSl age groups
m d their age-matched C57BL/6 controls (Fig. 16). This increase correlated precisely
with increased plaque-associated A{) immunoreactivity in the 6 and 12 month old
APP/PSl mice (Fig. 16). Analyses of hippocampi from all groups showed similar results
to the temporal cortex (data not shown). These data supported the notion that microglial
activation in AD and its mouse models may be a consequence o f Ap fibril interaction.
However, to validate an involvement o f tyrosine kinase act ivity in microglial phenotype
changes during disease, APP/PSl brains were next immunostained with antiphosphotyrosine antibody as an indirect m (hod to assess overall tyrosine kinase activity
changes. Immunostaining mouse brains with anti - phosphoty rosine antibody. 4G10,
demonstrated positive microglial-Iikc as well as neuronal-like immunoreactivity (Fig. 17).
Counting plaque-associated 4G10 positive staining as putative microglia demonstrated a
trend of age-associated increase in APP/PSl temporal cortex staining with a significant
increase by 4 months o f age with significantly higher immunoreactivity at 6 and 12

months (Fig. i 7), Similar trends were observed in the hippocampus (data not shown).
These data validated that by 12 months o f age, this particular transgenic line had robust
phosphotyrosine microglial reactivity in association with A{) plaques providing us with
the appropriate time point for use.
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Figure 16. Microgliosis in the APP/PS1 model of AD positively correlated with
increased Aji plaque density. Serial coronal sections from 2 month, 4 month, 6 month
and 12 months old control (C57BL/6) animals and age-matched transgenic animals
(APP/PS1) (n*=6) were immunostained for (A) activated microglia (anti-C.D68) and Ap
(anti-4G8 antibody) plaques. Representative hemi sections are shown with select high
magnification panels. (8) Immunoreactivity densities from the temporal cortex region for
0 ) 6 8 and 4G8 were quantified, averaged and graphed (+/-SE) *p< 0.001 from 2 and 4
month APP/PS1 animals, "pO.OOl from 2, 4, 6 and 12 month wild type animals for
(1)68. "pcO.OOl from 2, 4 ,6 month wild type mice for 4G8, and $p<0.00l from 6 month
APP/PS1 animals.
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Figure 17. There was an age-dependant increase in total phospho-tymsinc immunopositive plaques in a transgenic mouse model of AD (APP/PS1). (A) Serial coronal
sections from 2 month, 4 month, 6 month and 12 months old control (C57BL/6) animals
and age-matched transgenic animals (APP/PS1) (n=6) were immunostained using
phospho-tyrosine antibody (4G10). (B) To omit the inclusion of neuronal
phosphotyrosine staining, 4G10 positive plaques were counted from the temporal cortex
and the hippocampus regions and averaged and graphed (+/-SE) *p<0.00l from 2 month
APP/PS1 mice, #p<0.001 from 2 month and 4 months APP/PS1 animals, $p<0.001 from
2 , 4 and 6 month APP/PS1 animals.

Dasatinib infusion decreasedphospho-Src but not phospho-Lyn levels in APP/PSI mice
Based upon the temporal profiling of microgliosis we next determined whether
inhibition of tyrosine kinase activity could attenuate the miciugiial reactivity in this line.
Based upon our in vitro data we hypothesized that dasatinib treatment would attenuate
the Ap-associated increase in tyrosine kinase activity, particularly Src, and subsequent
inflammatory changes in the mice. In order to answer this question, 13 month old
APP/PSI female mice were sub-cutaneously infused with dasatinib for 28 days. Dasatinib
infusion significantly decreased protein phosphotyrosine levels in the hippocampus but
not the temporal cortex compared to vehicle infused control animals (Fig. 18). More
importantly, dasatinib infusion significantly decreased levels of active, phospho-Src in
both temporal cortex and hippocampus compared to vehicle treated mice (Fig. 18).
However, dasatinib infusion had no effect on the active, phosphorylated levels of the
related Si

unity member, Lyn kinase, demonstrating some specificity of the drug (Fig.

18). These data demonstrated that a subcutaneous route o f dasatinib delivery was able to
inhibit levels o f active Src in the brains of the APP/PS1 mice.
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Figure 18. Dasatinib infusion reduced protein phosphotyrosinc and active phosphoSrc kinase levels in APP/PS1 brains in vivo. Vehicle or dasatinib (500ng/kg/day) was
infused sub-cutaneously into 13-month old APP/PS1 for 28 days (n=7). Hippocampus
and temporal cortex regions were dissected from the left hemispheres and flash frozen for
protein analyses. The frozen tissue was lysed in RIPA with protease inhibitor. (A)
Hippocampal and (B) temporal cortex brain lysates from control (13 month APP/PS1 j,
vehicle infused, and dasatinib infused animals were used for Western blot analyses using
pTyr (4G10), pSrc, pLyn, a-tubulin, Src, and Lyn antibodies. (C) Optical densities were
averaged and graphed (+/-SEM) for hippocampus *p< 0.05, ***p< 0.001 from control
and for (D) temporal cortex *p<0.05 from control.
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Dasatinib infusion decreased TNF-a levels and microgliosis in APP/PSI mice
Based upon the encouraging findings that dasatinib was able to exert brain effects
and inhibit active Src levels we expected that dasatinib infusion should also attenuate
microgliosis and TNFa secretion as observed in our in vitro findings. Dasatinib infusion
significantly decreased TNFa levels in both the hippocampus and temporal cortex
correlating with the decrease in active Src levels and demonstrating a clear brain anti
inflammatory effect of the drug (Fig. !9). Moreover, levels o f CD68, the reactive
microglial marker protein, were significantly decreased in the hippocampus o f dasatinib
infused brains but not the temporal cortex. This data demonstrated that dasatinib
inhibition of brain active Src levels correlates with a significant anti-inflammatory,
microglial-inhibitory effect in APP/PSI mice. Interestingly, these effects appeared most
robust in the hippocampus compared to the temporal cortex (Fig. 18,19).
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A

C

Hippocampus

Figure 19. Dasatinib infusion reduced CD68 and TNF-a protein levels in
hippocampus of 13 month old APP/PS1 brains in vivo. (A) Hippocampal and (B)
temporal cortex brain lysates from control (n=7), vehicle (n=6), and dasatinib infused
animals (n=7) were used for Western blot analyses for activated microglia (using CD68
antibody) and pro-inflammatory cytokine TNF-a (anti-TNF-a antibody) antibodies with
a-tubulin as the loading control. (C) Optical densities were averaged and graphed (+/SEM) for hippocampus **p< 0.01 from controls and (D) temporal cortex *p<0.05 from
controls.

Dasatinih infusion did not alter APP, Aft, or synaptic protein levels in APP/PSI mice
T '"'.amine the breadth o f changes that might result from dasatinih infusion we
also determined whether adverse effects on neurons, astrocytes, or Aft deposition resulted
from drug treatment in addition to the anti-inflammatory, microglial-inhibitory changes.
However, dasatinih administration had no effect on either total APP levels or Aff levels in
the hippocampus or temporal cortex o f treated mice compared to vehicle controls (Fig.
20). In addition, dasatinih treatments did not increase levels of the reactive astrocyte
marker protein, GFAP, in the infused animals compared to vehicle control mice (Fig. 8).
Finally, dasatinih treatment did not have any significant effects on levels o f either
presynaptic (synaptophysin) or post-synaptic (PSD 95) proteins in either the temporal
cortex or hippocampus compared to vehicle treated mice (Fig. 20). These data
demonstrated that the Src inhibitory, anti-inflammatory, microglia-inhibitory effects of
dasatinih treatment did not correlate with any adverse effects such as increased
astrogliosis, neuron or synaptic loss, and increased Aj3 deposition.
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Figure lO.Dasatinib infusion did not alter levels of AFP, Ajl, synaptic markers,
synaptophysin, PSD95, or GFAP in hippocampus of 13 month old APP/PSI brains
in vivo. (A) Hippocampal and (B) temporal cortex brain lysates front control (n-7),
vehicle (n=6), and dasatinib (n=7) infused animals were used for Western blot analyses
using anti-AP clone 6E10 antibody, anti-APP, anli-synaptophysin, anti~PSD95 and antiGFAP antibodies. (C) Optical densities were averaged, and graphed (+/-SEM) for
hippocampus and (D) temporal cortex.
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Da,natinib infusion decreased immunoreactivUy fo r protein pkosphotyrosine, phospho-Src
and CD68 in APP/PSI mice
I o provide qualitative assessments along with the quantitative Western blot
analyses, inimunohistochcmical studies were also performed from the treated animals. As
expected, protein phosphotyrosine immunoreactivity in dasatinib infused mouse brains
appeared dramatically less then vehicle treated mice in both the hippocampi ' and
temporal cortex (Fig. 21). A similar trend o f decreased immunoreactivity was observed
for active phospho-Src in dasatinib treated animals versus vehicle control? (Fig. 21).
Importantly, the decrease in immunoreactivity was observed in plaque-associated
microglial-like cells demonstrating that the significant decreases in active Src and
phosphotyrosine levels observed by Western blot analyses were a reflection o f microglial
changes due to the drug. Also as predicted, levels o f CD68 reactive microglial
immunoreactivity in dasatinib infused mice was noticeably decreased compared to
vehicle treated mice in both the hippocampus and temporal cortex (Fig. 21). Consistent
with the Western blot analysis, GFAP immunoreactivity for reactive astrocytes was not
visually different between dasatinib and vehicle infused mice in either temporal cortex or
hippocampus (Fig. 21). The qualitative immunostaining findings corroborated the
quantitative Western blot analyses and validated that the significant decreases in pSrc
levels were largely due to decreased microglial immunoreactivity. our intended target for
the drug.
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Figure 21. Dasatinih infusion attenuated microgliosis, protein phospho-tyresine
levels and active phospho-Src levels but not GFAP immunoreactfvity in Ilit
APP/PS1 model of AD. Right hemispheres from brains of dasatinih infused, vehicle
infused and 13 month old APP/PS1 controls animals were fixed, sectioned and
immunostained using anti-phosphotyrosine (4G10) antibody, CD68 antibody, and active.
phospho-Src (anti-pSre) antibody. Representative 10X sections from the CA1 region of
the hippocampus are shown with select high magnification fields.
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Aft plaque load was not affected by dasatinib infusions into the APP/PSJ mice
One possible consequence o f attenuated tyrosine kinase activity in microglia
could be inhibition o f phagocytic ability. It is well known, for instance, that tyrosine
kinase activity can affect macrophage phagocytic ability (Greenberg et al., 1996; Aderem
and Underhill. 1999; Fitzer-Altas et al., 2000). Therefore, inhibition o f Src or related
kinase activity might attenuate any ability microglia have to clear AJ5 deposits in the brain
producing an unwanted side-effect o f increased plaque load. Based upon the Western blot
analysis dasatinib treatment had no effect on altering APP or Apt levels in the brains of
mice (Fig. 21). However, to better assess whether the drug had any effects on insoluble
fibrillar deposits in the brain, quantitative immunostaining o f A|3 plaques was performed.
Dasatinib treatment had no effect on plaque load in treated mice compared to vehicle
controls in either the hippocampus or temporal cortex (Fig. 22). These data demonstrate
that the microglial-inhibitory effects of dasatinib do not result in unwanted effects o f
increasing A(i deposition or accumulation

67

A

AB (4G8)
Control

B

Vehicle

Dasatinib

Temporal Cortex

Hippocampus
2000

1800
1600
Q 1400
°

1200

|

1000

I 800

g

600
400
200

Control

Vehicle

0

Dasatinib

Control

Vehicle

Dasatinib

13-Month APP/PS1

13-Month APP/PS1

Figure 22. Dasatinib infusion did not change the Aft plaque toad in the brain of
APP/PS1 mice. Serial sections from right hemishperes o f brains o f dasatinib infused,
vehicle infused and 13 month old APP/PS1 mice were immunostained using anti-Afi
antibody, clone 4ti8. and quantified for plaque load. (A) Representative 1.25X sections
o f the brain hemipsheres are shown with select high magnification fields. (B) Optical
density measurements from the CA1 region o f hippocampus and temporal cortex regions
are shown +/- ST..
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Dasatinib infusion improved T maze performance in APP/PS1 mice
Although there was no effect of dasatinib treatment on AfS deposition, the clear
and somewhat specific effect of Src inhibition correlating with anti-inflammatory and
microglial-inhibitor)' effects provided an opportunity to assess whether dasatinib could
also provide cognitive improvement to the mice. After treatments, spontaneous
alternations from dasatinib treated, vehicle treated, and control animals were quantified
during 1' maze analyses. This particular model of spatial memory was selected based
upon its sensitivity of detection o f cognitive deficit in AD mouse models (Stewart et ah,
2011) and its preference for detecting changes in hippocampal-based performance
differences (Duncan and Duncan, 1971; Loesche and Steward, 1977) since our most
significant effects o f drug were observed in hippocampus. Dasatinib infused animals
demonstrated improved cognitive performance represented by a significant increase in
spontaneous alternations compared to vehicle treated mice (Fig. 23). These data validated
that subcutaneous administration o f the Src/Abl tyrosine kinase inhibitor, dasatinib, is
able to provide cognitive enhancing effects to APP/PS1 mice while attenuating microglial
activation and pro inflammatory cytokine, TNFa, levels in the brain.
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Figure 23. Dasatinib infused APP/PS1 iniec demonstrated increased spontaneous
alternations during T maze testing. Dasatinib or vehicle DMSO was infused sub
cutaneously via min-osmotic pump into 13-month old APP/PS1 mice (n -7 , for 28-days.
T-maze performance and numbers o f spontaneous arm entry alternations was assessed on
day 29. Mean number o f alternations +/- SE were graphed. (*p<0.05 vs control,
***p<0.001 vs. vehicle).
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CHAPTER 5
CHARACTERIZATION OF NOVEL SRC FAMILY KINASE INHIBITORS
Although dasalinib exerted anti-inflammatory effects in vivo correlating with
decreased levels of active Src, it had no effect on active Lyn. Based upon the data that
increased active pLyn levels were observed in AD brains, Lyn kinase still represents a
valid microglial inhibitory target in AD. In order to identify a Lyn selective inhibitor, a
high throughput screening in vitro and kinase assay was performed screening over 20,000
compounds. Four novel compounds were chosen to be characterized in cellular assays for
their ability to inhibit two target kinases, Src and Lyn. The murine BV2 microglial cell
line and primary microglial cultures were selected as the screening cells. These novel
drugs, LDDN-00^3499, LDDN-0075935, LDDN-0125694 and LDDN-0127164, were
used to treat microglial BV2 cells to determine their ability to decrease basal total protein
phosphotyrosine levels as well as active, phosphorylated forms of Src. Lyn and ERK
kinases. O f the four drugs, LDDN-0003499 dose-dependently inhibited active,
phosphorylated Lyn kinase levels. To determine whether the drug could attenuate
stimulated kinase activity, A[3 and LPS stimulated primary microglia cultures were
treated with LDDN-0003499 to assess effects on active levels o f Src and Lyn. This study
characterized the ability of LDDN-0003499 to attenuate microgliosis via particularly
Lyn inhibition in vitro. Further work is required to modify this compound for in vivo
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testing to determine whether it ean attenuate microgliosis and Lyn activity in an AD
mouse model.
Assessment o f LDDN drugs effects on viability
Before screening drugs for any ability to alter cellular kinase activities, we first
determined whether the drugs were toxic or not. Microglial BV2 cells were treated with
LDDN-0003499, LDDN-0075935, LDDN-0125694 and LDDN-0127164 with increasing
concentrations ranging from 0.5nM up to 50 pM for 24h. The media was removed and
used for LDH release assays to determine cell viability. Quantitation o f LDH released
from the media following drug treatment demonstrated that none o f the four drugs were
toxic at any o f the concentrations used for treatment (Fig. 24). For subsequent
experiments to assess effects on tyrosine kinase inhibition, 0.5nM, 5nM, 50nM, 0.5pM,
5pM and 50pM concentrations were chosen for treatment o f BV2 cells line as w'ell as
primary microglia cultures.
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Figure 24. LDDN drugs were not toxic to microglial BV2 cells. Microglial BV2 cells
were untreated (control), vehicle treated, or treated with 0.5nM, 5nM. 50nM, 0.5 pM,
5pM and 50 pM (A) LDDN-000.,499, (B) LDDN-0075935, (C) LDDN-0125694 and (D)
LDDN-0127164 for 24h. Media was removed and used for an LDM release assay to
determine cell viability. 3 independent experiments with 8 replicates each were
performed and absorbance values graphed and averaged +/- SO.
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LDDN-0003499 decreased total protein phosphotyrosine level in microglia BV2 cells
In order to validate a tyrosine kinase inhibitory ability of the drugs in cells, the
mouse microglia cell line, RV2, was treated with increasing concentrations o f LDDN0003499, LDDN-0075935, LDDN-0125694 and LDDN-0127164. O f the four drugs
analyzed using dot blot analyses, 50pM LDDN-0003499 was able to significantly
decrease the levels of total protein phosphotyrosine in these cells as compared to vehicle
treated cells (Fig. 25). LDDN-0075935, LDDN-0125694 and LDDN-0127164 were not
able to inhibit protein phosphotyrosine levels at the concentrations used. The cell lysates
were also analyzed using Western blot analysis to completely resolve the protein
phospho-tyrosine profile. A dose-dependent inhibition o f overall protein phosphotyrosine
levels was observed with LDDN-0003499 whereas the other 3 drugs failed to show any
inhibitory effects in these cells.
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Figure 25. LDDN-0003499 attenuated total protein phosphotyrosinc levels in the
microglial IW2 cell line. Microglial BV2 cells were vehicle treated or treated with
i. 0.5 |.iM, 5pM and 50 pM (A) LDDN-0003499, (B) LDDN-0075935,
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(C) LDDN-0125694 and (D) LDDN-127164 for 24h. Cells lysates were used for dot-blot
analyses using anti-phosphotyrosine (4G10) antibody with a-tubulin as the loading
control. Optical densities were graphed and averaged +/- SD (*p<0.05 vs. control and
vehicle). (E ) Cell lysates were resolved via SDS-PAGE and Western blotted using antipTyr and a-tubulin (loading control) antibodies. A representative Western blot is shown.
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LDDN-0003499 dose-dependent ly attenuated levels o f active, phosphorylated Lyn in BV2
cells.
Although the drugs were tested for an ability to decrease total protein
phosphotyrosine levels, the in vitro kinase assay target for these drugs was Lyn kinase.
Therefore, in order to validate a cellular Lyn inhibitory ability o f these drugs, BV2 cells
were treated with increasing concentrations o f LDDN-0003499, LDDN-0075935,
LDDN-0125694 and LDDN-0127164 for 24h. Cell lysates were analyzed using dot blot
analyses for pSrc, pLyn and pERK levels. Quantitation o f the blots demonstrated a dosedependent decrease in active, phosphorylated Lyn kinase levels in the cells treated with
LDDN-0003499 (Fig. 26). LDDN-0075935 and LDDN-0127164 were not able to
attenuate or affect pLyn levels in the cells at any o f the doses (Fig. 27-29). LDDN0125169 inhibited pLyn at a number o f doses, as compared to vehicle treated cells, but
this response was not dose dependent. LDDN-0003499 was also able to significantly
reduce pSrc levels in these cells, although the response was not dose dependent. LDDN0075935 and LDDN-0127164, again did not affect any change in pSrc levels. LDDN0125169 was able to inhibit pSrc at a lower dose o f 0.5nM only, as compared to vehicle
treated cells. As an unrelated kinase control, each drug was tested for ability to alter
active levels o f the Ser/Thr kinase extracellular signal regulated kinase 2 (ERK2). There
were no changes in active, phosphorylated ERK kinase levels in BV2 cells with treatment
o f any o f the four drugs at the concentrat ions used. Western blot analysis of the
microglial BV2 cells treated with LDDN-3499 revealed a dose-dependent attenuation in
pLyn levels, but not pSrc levels. The other three drugs failed to affect any changes in
acti ve levels o f Src, Lyn or ERK kinases.

77

This data suggests that LDDN-0003499 may be a promising drug for specifically
inhibiting active pLyn levels in a dose dependant manner in microglia. To assess the

specific kinase inhibition on microgliosis, SOpM o f LDDN-0003499 was chosen to
obtain a maximal inhibitory e f ect on tyrosine kinases in stimulated primary microglia
cultures.
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Figure 26. LDDN-0G03499 dose-dcpendcntly attenuated active, phosphorylated Lyn
levels in BV2 cells. Microglial RV2 cells were vehicle treated, or treated with 0.5nM.
5nM, 50nM, 0.5 pM, 5pM and 50 pM LDDN-0003499 for 24h. Cells lysate*for dot-blot analyses with anti-pSre n \ r -l ie,? (A), anti-pLyn (Tyr 396) (B) and anti,u .RK (C) antibodies with Src, Lyn and ERK2 antibodies as their respective loading
controls. Optical densities were graphed and averaged +/- SD (*p<0.05, **p<0.0l vs.
control and vehicle). (D) Cell lysates were resolved via SDS-PAGE and western blotted
using anti-pSrc, anti-pLyn, anti-pERK, anti-c-Src, anti-Lyn and anti-ERK2 antibodies. A
representative Western blot is shown.
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Figure 27. LDDN-0075935 did not attenuate active, phosphorylated Src, Lyn, or
ERK levels in BV2 cells. Microglial BV2 cells were vehicle treated, or treated with
0.5nM, 5nM, 50nM, 0.5 pM, 5pM and 50 pM LDDN-0075935 for 24h. Cells lysates
were used for dot-blot analyses with anti-pSrc (Tyr416) (A), anti-pLyn (Tyr 396) (B)
and anti-pERK (C) antibodies with Src, Lyn and ERK2 antibodies as their respective
loading controls. Optical densities were graphed and averaged +/- SD. (D) Cell lysates
were resolved via SDS-PAGE and Western blotted using anti-pSrc, anti-pLyn, antipIvRK. anli-c-Src. anti-Lyn and anti-ERK2 antibodies. A representative Western blot is
shown.
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Figure 28. LDDN-0125694 did not dose dependency attenuate active,
phosphorylated Src, Lyn, or ERK levels in RV2 cells. Microglial BV2 cells were
vehicle treated, or treated with 0.5nM, 5nM, 50nM, 0.5 pM, 5pM and 50 pM LDDN0075935 for 24h. Cells lysates were used for dot-blot analyses with anti-pSre (Tyr 416)
(A), anti-pLyn (Tyr 396) (B) and anti-pERK (C) antibodies with Src. Lyn and ERK2
antibodies as their respective loading controls. Optical densities were graphed and
averaged +/- SD. (I)) Cell lysates were resolved via SDS-PAGE and Western blotted
using anti-pSrc, anti-pLyn, anti-pERK, anti-c-Src, anti-Lyn and anti-ERK2 antibodies. A
representative Western blot is shown.
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Figure 29. LDDN-0127164 did not attenuate active, phosphorylated Src, Lyn or
ERK levels in BV2 cells. Microglial BV2 cells were vehicle treated, or treated with
0.5nM, 5nM, 50nM. 0.5 pM, 5pM and 50 liM LDDN-0075935 for 24h. Cells lysates
were used for dot-blot analyses with anti-pSrc (Tyr 4 16) (A). anti-pLyn (Tyr 396) (B)
and anti-pERK (C) antibodies with Src, Lyn and ERK2 antibodies as their respective
loading controls. Optical densities were graphed and averaged +/- SD. (D) Cell lysates
were resolved via SDS-PAGE and Western blotted using anti-pSrc, anti-pLyn, anti
pERK, anti-c-Src, anti-Lyn and anti-ERK.2 antibodies. A representative Western blot is
shown.
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LDDN-0003499 attenuated an Afi dependent increase in active phosphorylated Src and
Lyn kinases levels in primary microglia cultures.
Based on our earlier data and other work, it has been very well established that
fibrillar Af3 and LPS can act as pro-inflammatory stimuli for microglia in the brain.
However the primary rationale for this drug discovery effort was to identify small
molecule capable o f decreasing Ap stimulation o f microglia. To assess the ability of
LDDN-0003499 to decrease Ap or LPS stimulated tyrosine kinase changes in primary
microglia cultures, cells were first stimulated with increasing concentrations o f Apf and
LPS to determine a concentration with adequate changes in increased active Lyn levels.
As expected there was a dose dependent increase in total protein phosphotyrosine levels
observed with Ap treatment of the microglia (Fig.30). Ap also stimulated increase in
active, phosphorylated form o f Src and Lyn kinases. Upon pretreatment on primary
microglia cultures with 50pM LDDN-0003499, the Ap stimulated increase in pLyn and
pSrc levels was attenuated, as compared to vehicle treated cells.
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Figure 30. LDDN-0003499 attenuated an AP-dependent increase in active,
phosphorylated Src and Lyn levels in prim ary microglia cultures. (A) Primary
microglia cultures were untreated, vehicle treated (v) or treated with 5 pM, lOpM, 20 liM
A (3 or 25ng/ml LPS for 5 minutes. Cell lysates were resolved by SDS-PAGE for antipTyr (4G10), anti-pSrc, anti-Lyn, anti-pERK, anti-Src, anti-I,yn, anti-ERK and anti-cc84

tubulin antibodies. Representative Western blots are shown. Primary microglia cultures
were vehicle treated (v) or treated with 10 pM Ap in presence and absence o f 50 pM
LDDN-0003499. (B) Cell lysates were resolved by SDS-PAGE and blotted using antipSrc and anti-pLyn antibodies with Src and Lyn as loading controls. (C) Optical densities
were averaged and graphed +/- SD (*p<0.05, **p<0.01 vs. AP treated cells)
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LDDN-0003499 attenuated LPS-mediated secretion o f the pro-inflammatory cytokine,
TNF-a, in primary microglia cultures.
In order to determine whether the LPS-stimulated change in increased active
tyrosine kinase levels was required for changes in phenotype, increased secretion of the
pro-inflammatory cytokine, TNF-a. was quantified from the primary microglia cultures
in the presence or absence of LDDN-0003499. LPS stimulated a significant increase in
TNF-a secretion compared to control or vehicle treated microglial cells (Fig. 31). This
increase in TNF-a secretion was attenuated by pretreatment with 50pM drug with no
effect of cellular viability (Fig. 31). The data demonstrated that inhibition of Src family
kinase activity was sufficient to prevent microglia from acquiring are reactive secretory
phenotype upon pro-inflammatory stimulation in vitro.
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Figure 31. LBDN-0003499 attenuated LPS stimulated-microglial secretion of the
proinflammatory cytokine, TNF-a. Primary microglia were unstimulated (control),
DMSO vehicle treated (v), treated with 0.5 uM. 5uM and 50 uM LDDN-0003499 or
stimulated for 24 hours with 25ng/ml LPS in the presence/absence of the 50 pM LDDN0003499 drug. (A) Media was collected from the treated cells and used to quantify
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changes in TNF-a secretion via ELISA. Secreted values were averaged +/-SD (*p< 0.05).
(B) Media from treated cells was also used for to „ ssess cell viability via the LDH release
assay. Absorbance values (490nm) were averaged+/-SD.
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CHAPTER 6
DISCUSSION
This work demonstrates that AP oligomers and fibrils stimulate microglial
activation in vitro via a tyrosine kinase associated pathway that results in increased
secretion of the proinflammatory cytokine, TNF-u. It is possible to attenuate the
oligomer-stimulated microglial phenotype change using a non-receptor tyrosine kinase
inhibitor, dasatinib. The in vitro observations of oligomeric stimulation of microglia were
validated in vivo demonstrating that intracerebroventricular infusion of oligomeric Ap
also stimulated increased microgliosis via a tyrosine kinase-dependent mechanism that
was attenuated by co-delivery of dasatinib. Finally, the rodent findings correlated with a
reactive microglial increase in protein phospho-tyrosine, p-Lyn and p-Src levels in AD
brains compared to controls. Since total protein phosphotyrosine, more specifically
active, phosphorylated Lyn and Src kinase are associated with plaques as well as distinct
microglia in AD brains, role of fibrillar Ap in activation of microglia phenotype cannot
be ruled out. Collectively, all this data suggests that amyloid dependent microgliosis
occurs through a tyrosine kinase dependent pathway. This mechanism of activation could
prove to be very important therapeutically for attenuating pro-inflammatory microglial
activation. In order to further understand the signaling pathway involved in amyloid
based microglial activation, for pharmacological intervention purposes, a transgenic
mouse model of AD, APP/PS1 mice, were also studied to assess protein phosphotyrosine
changes with age. An age-dependent increase in plaque deposition in APP/PS1 mice
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correlated with increased phosphotyrosine immunoreactivity and microgliosis in these
mice. In order to assess whether inhibition of tyrosine kinases attenuated proinflammatory changes, dasatinib was subcutaneously infused into aged (13 month) old
APP/PS1 mice with established plaques and reactive microglia. The infusions
demonstrated that dasatinib attenuated overall tyrosine phosphorylation and active Src
levels, in particular, in the hippocampus. The drug did not affect A|3 plaque load but
reduced microgliosis and TNF-a levels in these animals without affecting other cell
types, neurons and astrocytes. Moreover, dasatinib provided a significant increase in
cognitive performance in correlation with this anti-inflammatory action. Collectively,
these findings support the idea that A(3 fibrils and oligomers can serve as a microglial
activating ligand in disease contributing to their proinflammatory phenotype and use of
selective non-receptor tyrosine kinase inhibitors is an effective strategy to limit
microglial-mediated changes during disease (Fig. 32).
Apn o r A p f

Microgliosis associated —
increased tyrosine
kinase activity
Inflammation (IL-6, IL-8,
MCP-1, TNF-a)
Figure 32: Amyloid dependent microgliosis occurs through a Src kinase activation

pathway
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Although it has been suggested that A|3-stimulated microglial activation
contributes to the pathophysiology of AD (Banati et al., 1993; Del Bo el al., 1995;
Giulian et al., 1995; Klegeris et al.. 1997; Combs et al., 2000; Combs et al., 2001a;
Combs et al., 2001b; Floden and Combs, 2006) and a broad range of microglial secreted
inflammatory markers are elevated in AD brains, including IL-la, IL-lp, TGF-p and
TNF-a (Akiyama et al., 2000; Jara et al., 2007), enthusiasm for an anti-inflammatory
approach to treating AD has decreased, in part, due to lack of drug efficacy of a number
of human trials that targeted cyclooxygenase (Cox) activity in AD patients (Rogers et al.,
1993; Scharf et al., 1999; Aisen et al., 2002; Aisen et al., 2003; Thai et al., 2005). Indeed,
Cox inhibition during later stages of disease had adverse effects and c fry demonstrated
protection when administered long-term to asymptomatic individuals (Breitner et al.,
2011). One possibility for the lack of efficacy of Cox inhibitors could be because Cox
enzymes are expressed by multiple cell types in the brain and general drug inhibition has
no cellular selectivity. Another possibility for the failed efficacy is that Cox 1 or 2
enzyme activities are simply not relevant targets for attenuating microglia-dependent
changes. For this reason the direct signaling response initiated in microglia upon Ap
oligomer and fibril stimulation was the focus of this study, ft has been reported from both
AD brains (Tillotson and Wood, 1989a, b; Karp et al., 1994) and mouse models
(Frautschy et al., 1998; Combs, 2009) that elevated protein phosphotyrosine levels are
reliable markers of reactive microglia associated with plaques.
In spite of that fact that the specific stimuli driving microgliosis during disease
may be heterogeneous, a common finding from our rodent in vitro and in vivo findings
and AD brains is the increase in protein phospho-tyrosine levels. Our prior in vitro work
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has demonstrated that specific non-receptor tyrosine kinase activities including Lyn and
Syk are involved in the oligomer-dependent activation of microglia (Sondag et al.. 2009)
which correlated well with the increased phospho-tyrosine immunoreactivity observed in
the intracerebroventricular infused animals. In vitro studies using monocytic lineage cells
(McDonald et al., 19c 8; Combs et al., 2001a; Bamberger et al., 2003) and microglia
(Combs et al., 1999; Sondag et al., 2009) have demonstrated that fibrillar A(3 stimulates a
specific increase in overall protein tyrosine phosphorylation. Although numerous tyrosine
kinases are expressed in microglia and it is likely that the temporal profile of kinase
activities changes during chronic oligomer stimulation. During disease, stimulation with
fibril, oligomer or other ligands may be superimposed (Sondag et al., 2009). Based upon
the human disease and in vitro data, we demonstrated that active forms of non-receptor
tyrosine kinases, Src and Lyn, are increased in reactive microglia. Indeed, the microglial
phospho-Src and phospho-Lyn immunoreactivity changes observed in the AD brains is,
to the best of our knowledge, a new contribution to the field. Thus, we have begun to
identify particular kinase activities that may be responsible for the increase in
phosphotyrosine immunoreactivity and microgliosis during disease.
This common change of increased forms of active non-receptor tyrosine kinases
in the rodent and human findings served as the rationale for selecting a somewhat broad
specificity agent, dasatinib, for its ability to attenuate the function of several different
kinases, in particular the Src family members (Lombardo et al., 2004; Das et al., 2006).
The ability of dasatinib to limit protein phospho-tyrosine changes and cytokine secretion
suggests that targeting kinase activity is a viable anti-inflammatory strategy for treating
AD. It is interesting to note that limiting tyrosine kinase-dependent microgliosis is not the
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only attractive reason for targeting these enzymes. For instance, tau phosphorylation is
regulated via activity of the tyrosine kinase Abl modulating Cdk5 activation in a
transgenic mouse model of AD (Alvarez et ah, 2004; Cancino et ah, 2009). Very
recently, another tyrosine kinase inhibitor anti-cancer drug, imatinib, has been shown to
target gamma-secretase activating protein as a therapeutic approach for Alzheimer’s
disease in a rodent model (He et ah, 2010). Not surprisingly, recruitment of Src and Abl
tyrosine kinases to APP has been demonstrated (Trommsdorff et ah, 1998). Prior work
has also verified an increased association of Src with APP in human diseased brains
(Austin et ah, 2009). Although our intracerebroventricular infusions, transgenic animals
and in vitro studies, focused on oligomer and fibril stimulated mechanism of
proinflammatory microgliosis in AD, it is likely that a heterogeneous mixture of changes
during disease offers the possibility that inhibition of this class of kinases will be
attractive from a number of different therapeutic perspectives.
Both in vitro data and in vivo experiments demonstrated that an oligomeric
preparation of Ap corresponding roughly to the size of SDS-stable trimer/tetramers at
initial stimulation could drive microgliosis via a tyrosine kinase-dependent mechanism
that correlated with a similar change in protein tyrosine phosphorylation in human
diseased brains. Despite the fact that the oligomeric Ap was delivered in a HDL solution
to ensure its stability as an oligomeric preparation while in the pump, it is possible that
the multimeric species changed after infusion into the brain over the time course of 14
day administration resulting in higher molecular weight species. However,
immunohistochemical analyses using anti-oligomer antibodies to observe for oligomeric
Ap immunoreactivity strongly suggests by the thioflavin negative. A ll /111 positive nature
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ol the deposited A|3, that the peptide was retained in an oligomeric and not fibrillar form.
The possibility that higher order multimers and possibly some undetected fibrils did
accumulate in the tissue during the infusion period along with, perhaps, co-deposition of
endogenous Af3, cannot be excluded. With the understanding that there may be some
multimeric species of A[3 involved, along with the SDS-stable trimeric/tetrameric infused
A(3, the changes observed in microgliosis and the ability of dasatinib to attenuate those
changes remain novel and relevant to A|3-dependent microglial changes during disease.
With regard to human disease, we certainly do not exclude the likelihood that fibrillar
deposits of A(3 are also potent stimuli of microglia. As already mentioned, increased
protein phospho-tyrosine staining from both AD brains and transgenic mouse models
(Wood and Zinsmeister, 1991; Frautschy et ah, 1998) have characterized microglial
activation in association with A|3 plaques. Furthermore, prior work has demonstrated that
fibrils also stimulate microglia in vitro via tyrosine kinase-mediated mechanisms
(McDonald et ah, 1997; Combs et ah, 1999). However, histologic analysis of human
brains demonstrated that some reactive microglia were associated with oligomeric A3 as
well, a finding not widely reported. In addition, many phospho-tyrosine immunoreactive
microglia in diseased brains were not associated with any observable A3 deposits
suggesting that non-deposited A3 oligomers or other molecules could be activating these
cells as well. Therefore, we propose that oligomers are one of the stimuli driving
microgliosis during disease but recognize a likely role of fibrils as well as possible still
unnamed ligands. It is for this reason that we chose to examine fibril activation as well
both in vitro and in the APP/PS1 model. As expected, both oligomers and fibrils could
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activate microgiia via Src family activation in our rodent studies correlating well with the
increased pSrc/pLyn immunoreactivity from AD brains.
Validation that an orally available, FDA approved drug, dasatinib, was efficacious
in in vivo study supports the idea of therapeutic tyrosine kinase inhibition for AD.
Dasatinib (commercially, Sprycel) is used for treating chronic myeloid leukemia (Shah et
ah, 2004) and has the ability to cross the blood brain barrier (Porkka et al., 2008). We
have demonstrated that it also attenuates AP-dependent proinflammatory microgliosis
and inhibits disease relevant non-receptor tyrosine kinases, and improves cognitive
performance.
The effect of decreasing microglial active Src and brain TNFa levels does not
necessarily prove that these changes were responsible for the improved cognitive
performance observed in the transgenic ir use model of AD with subcutaneously infused
dasatinib. However, the in vitro data clearly demonstrated that dasatinib treatment and
Src inhibition led to attenuated TNFa secretion providing correlative evidence that Src
inhibition in microglia in vivo contributed to the decrease in TNFa observed. Moreover,
recent human data using TNFa neutralizing drugs demonstrated cognitive improvement
in AD patients (Tobinick and Gross, 2008) suggesting that diminished TNFa levels in the
mice could have contributed to the cognitive improvements observed. We also appreciate
that dasatinib treatment may effect a number of other kinases in vitro and in vivo and
numerous cells may express Src. Non-receptor Src family tyrosine kinases are expressed
widely in the mammalian CNS and are known to play a role in proliferation and
differentiation of the CNS (Yoshimura et al., 1981; Alema and Tato, 1987; Haltmeier and
Rohrer, 1990; Meeker et al., 1991; W ongetal., 1992; Barone and Courtneidge, 1995;
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Taylor and Shalloway, 1996; Broome and Hunter, 1997; Klinghoffer et al., 1999;
Tatosyan and Mizenina, 2000). Indeed, Src family kinase activities are crucial for
synaptic plasticity, including learning and memory (Grant et al., 1992; Maness, 1992;
Grant and Silva, 1994; Kojima et al., 1997; Sinai et al., 2010). Therefore any strategy to
manipulate activity of these enzymes in the brain should be carefully considered. By
demonstrating specificity of dasatinib for Src versus the related family member Lyn in
vivo as well as a clear improvement in cognitive performance, we suggest that reagents
such as dasatinib can form the basis for not only human testing consideration but, more
importantly, for further drug development.
This study intentionally focused on animals at 13 months of age with established
plaques and reactive microglia to test the efficacy of our anti-inflammatory strategy in
late-stage disease. However, it will be important in future work to determine if a strategy
of kinase inhibition can attenuate or delay behavioral decline or microgliosis in earlier
stage disease. Although our longitudinal assessment in these mice suggested that
phosphotyrosine immunoreactive microglia correlated with increased fibrillar plaque
deposition, our prior work and our infusion data indicated that soluble oligomeric forms
of A[3 were also potent stimuli of microglia responsible for initiating a unique type of
tyrosine kinase-based signaling response (Sondag et al., 2009). Therefore, fully
determining the specific signaling pathways involved in different forms of A(3 stimulation
of microglia may offer a strategy for inhibiting specific tyrosine kinase activities at
different disease time points to maximally produce anti-inflammatory effects.
Based on all the data thus far, we suggest amyloid-dependent microgliosis occurs
via a Src kinase activation mechanism and this pathway is an important therapeutic target
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in the prevention of AD. This work dealt with using a general non-receptor tyrosine
kinase inhibitor, dasatinib, that shows affinity for a number of non-receptor tyrosine
kinases including Src, Lyn, Fck and Yes. Dasatinib has higher affinity for Src and our in
vitro and in vivo findings suggest that the drug has been effective in attenuating active
Src levels. However, in human disease, another non-receptor tyrosine kinase, Lyn has
been implicated in reactive plaque associated microglia. The Src family member, Lyn
kinase has an important role in regulating immune cell phenotype. Lyn has been shown to
physically associate with a number of hematopoetic cell surface receptors including BCR.,
CD40, LPS receptor and the FceRl complex. Kinase dead mice, with mutations
associated with loss of activity of Lyn show attenuated autoimmune disease, normally
associated with Lyn deficiency (Verhagen et ai., 2009) indicating a role of Lyn in B Cell
regulation. Lyn also is an important target role in prostate cancer therapies (GoldenbergFurmanov et al., 2004). Therefore, identifying the Lyn selective inhibitor to attenuate
microgliosis in general and not just associated with AD, may prove to be crucial for
therapeutically targeting several diseases. Based upon the observations that AD brains
showed increased levels of pLyn in tissue lysates as well as plaque-associated
immunoreactivity of active, phcsphorylated Lyn, Lyn cannot be excluded as a valid target
for attenuation of Ap-associated microgliosis (Fig. 33). Following a high throughput
screening kinase assay, four novel compounds were identified based upon their in vitro
ability to inhibit Lyn. We further defined their ability to inhibit Lyn kinase basally as well
in stimulated microglial in vitro models. We demonstrated that LDDN- 0003499, one
compound in particular, was able to inhibit basal active, phosphorylated Lyn levels in the
BV2 microglial cell line. LDDN-0003499 also decreased le vels of active Lyn and Src in
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Ap and LPS stimulated microglia. Although this study was a characterization of the drugs
in an in vitro system, there is a further need to modulate these drugs for in vivo use by
characterization of particular specificities. At this point, we conclude that Lyn is also a
relevant target for attenuating disease-associated microgliosis and propose that drug
dependent strategies such as this we has s undertaken may provide selective agents, for
assessing the importance of Lyn vs. Src for contributing to microgliosis.
Since microglia are the primary immune cells in CNS, they have been implicated
in a number of neurodegenerative disorders. As mentioned earlier, many proinflammatory and trophic factors are thought to be produced by activated microglia in
vitro (Giulian ef al., 1986; Hetier et al., 1988; Mallat et al., 1989; Sawada er ah, 1989;
Elkabes et a;., 1996; 1/liwa et ah, 1997). Microglia derived cytokines have been reported
to be elevated in many cases besides Alzheimer’s disease, including traumatic spinal cord
lesion, traumatic brain injury, stroke, HIV-infection and multiple sclerosis (Lindholm et
ah, 1987; Griffin et ah, 1989; Fagan and Gage, 1990; Merrill and Chen, 1991; Woodroofe
et ah, 1991; Taupin et ah, 1993; Buttini et ah, 1994; Merrill and Benveniste, 1996;
Bartholdi and Schwab, 1997; Benveniste, 1997). Despite of the findings that the stimuli
involved or the ligands responsible for microglial activation in disease conditions may be
different, the fact remains that modulating microglial phenotype in order to attenuate proinflammatory effects becomes imperative in prevention of the adverse effects of
microgliosis in all these diseases. Hence it is important to understand the mechanism(s)
underlying the activation of microglia for pharmacologic intervention studies.
Stimulation by fl-amvloid peptides results in increased expression ofCD40 on microglia
leading to elevated TNF-a secretion (Tan et ah, 1999b; Tan et ah, 2000). Microglial
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activation by either A[), CD40 ligand (CD40L) or LPS has been shown to involve
activation of the MAPK pathway as well (Combs et al„ 1999; Tan et ah, 1999a). Lyn
kinase has been shown to be involved in regulation of MAPK activation in microglia
(Combs et ah, 1999). Src is also reported to take part in regulation of MAPK in T cells,
following stimulation (Tsuji-Takayama et ah, 1997). Although, the mechanism of
Src/MAPK regulation are complex, it appears that, in general, Src activation leads to
downstream activation of MAP kinase, and production of neurotoxic and proinflammatory mediators. (Singer et ah, 2011) (Figure 33). The process can also occur
through acti vation of the PBKinase pathway (Combs et ah, 1999). Src may also activate
other signaling mediators like the JAK/STAT pathway leading to inflammatory gene
expression (Simon et ah, 2002; Simeone-Penney et ah, 2008). Therefore, the signaling
responses of pro-inflammatory signaling includes Src, activation is complex and is likely
stimulant dependent. Our data indicates a role for Lyn and Src kinases in reactive
microgliosis in AD. The retrospective studies involving NSAIDs possibly suggest that
microglial inhibition is the basis of the benefic al effects in AD. Clearly, further
experiments are needed to better understand the signaling cascade and the intracellular
interactions involved for driving microglial activation during disease. It is only by
detecting the intrinsic mechanisms of microglial activation that the most relevant target
and therefore, drugs can be developed.
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Figure 33. Schema*
,C ° f Srt/Lyn signaling pathway
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